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[57] ABSTRACT 
A novel class of peptide a-ketoamides useful for selectively 
inhibiting serine proteases. selectively inhibiting cysteine 
proteases. generally inhibiting all serine proteases. and gen-
erally inhibiting all cysteine proteases. having the formula 
M 1-AA-NH-CIIR:i-CO-CO-NR3R4• M 1-AA2-
AA1-CO-NR3R4. M 1-AA-AA-AA-CO-NR3R4• 
M 1-AA-AA-AA-AA-CO-NR3R4• or M 1-AA-
CO-NR3R4. 
3 Claims, No Drawings 
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PEPTIDE KETOAMIDES 
This is a continuation of application Ser. No. 08/246,511 
filed on May 20. 1994. now abandoned. which is a continu-
ation of Ser. No. 08/118.997 filed on Sep. 9, 1993. now 5 
abandoned. which is a continuation of Ser. No. 07/815.073 
filed on Dec. 27. 1991. now abandoned. 
ignated Z-Leu-Phe-CO-NH-Et which represents 
C6H5CH20CO-NH-CH(CH2CHMe2)-CO-NH-CH 
(CH2Ph)-CO-CO-NH-Et. 
3. Description of the Related Art 
Cysteine Proteases. Cysteine proteases such as calpain 
use a cysteine residue in their catalytic mechanism in 
contrast to serine proteases which utilize a serine residue. 
Cysteine proteases include papain. cathepsin B. calpains. 
and several vital enzymes. Neural tissues. including brain. BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to a novel class of peptide ketoa-
mides useful for selectively inhibiting serine proteases. 
selectively inhibiting cysteine proteases. generally inhibit-
ing all serine proteases. and generally inhibiting all cysteine 
proteases. Serine proteases and cysteine proteases are 
involved in numerous disease states and inhibitors for these 
enzymes can be used therapeutically for the treatment of 
diseases involving serine proteases or cysteine proteases. We 
have discovered that peptide cx-ketoamides can be con-
structed to inhibit selectively individual serine or cysteine 
proteases or groups of serine or cysteine proteases. We have 
found that peptide ketoamides which contain hydrophobic 
aromatic amino acid residues in the P 1 site are potent 
inhibitors of chyrnases and chymotrpysin-like enzymes. 
Ketoamides containing small hydrophobic amino acid resi-
dues at the P 1 position are good inhibitors of elastases. 
Inhibitors of elastases and chyrnases are useful as anti-
inflamrnatory agents. We show that peptide ketoamides 
which contain cationic amino acid residues such as Arg and 
Lys in the P 1 site will be potent inhibitors of trypsin and 
blood coagulation enzymes. These inhibitors are thus useful 
as anticoagulants. Cysteine proteases such as papain. cathe-
psin B. and calpain I and II are also inhibited by ketoamides. 
Ketoamides with aromatic amino acid residues in the P 1 site 
are good inhibitors for cathepsin B and papain. Thus. they 
would have utility as anticancer agents. Ketoamides with 
either aromatic amino acid residues or small hydrophobic 
alkyl amino acid residues at P 1 are good inhibitors of calpain 
I and II. These inhibitors are useful as neuroprotectants and 
can be used as therapeutics for the treatment of neurode-
generation and stroke. 
2. Nomenclature 
In discussing the interactions of peptides with serine and 
cysteine proteases. we have utilized the nomenclature of 
Schechter and Berger [Biochem. Biophys. Res. Commun. 27. 
57-162 (1967); incorporated herein by reference]. The indi-
vidual amino acid residues of a substrate or inhibitor are 
designated P 1• P 2• etc. and the corresponding subsites of the 
enzyme are designated S 1 • S2 • etc. The scissile bond of the 
substrate is S 1-S1'. The primary substrate recognition site 
of serine proteases is S1• The most important recognition 
subsites of cysteine proteases are S 1 and S2 • 
10 are known to possess a large variety of proteases. including 
at least two calcium stimulated proteases termed calpains. 
Calpains are present in many tissues in addition to the brain. 
Calpain I is activated by micromolar concentrations of 
calcium while calpain II is activated by millimolar concen-
!5 trations. In the brain. calpain II is the predominant form. but 
calpain I is found at synaptic endings and is thought to be the 
form involved in long term potentiation, synaptic plasticity. 
and cell death. Other Ca2"'" activated cysteine proteases may 
exist. and the term "calpain" is used to refer to all ea2+ 
20 activated cysteine proteases. including calpain I and calpain 
II. The terms "calpain T' and "calpain If' are used herein to 
refer to the micromolar and millimolar activated calpains, 
respectively. as described above. While calpains decade a 
wide variety of protein substrates. cytoskeletal proteins 
25 seem to be particularly susceptible to attack In some cases. 
the products of the proteolytic digestion of these proteins by 
calpain are distinctive and persistent over time. Since 
cytoskeletal proteins are major components of certain types 
of cells. this provides a simple method of detecting calpain 
30 activity in cells and tissues. Thus. calpain activation can be 
measured indirectly by assaying the proteolysis of the 
cytoskeletal protein spectrin, which produces a large. dis-
tinctive and biologically persistent breakdown product when 
attacked by calpain [Siman. Bandry. and Lynch. Proc. Natl. 
35 Acad. Sci. USA 81. 3572-3576 (1984); incorporated herein 
by reference]. Activation of calpains and/or accumulation of 
breakdown products of cytoskeletal elements has been 
observed in neural tissues of mammals exposed to a wide 
variety of neurodegenerative diseases and conditions. For 
40 example. these phenomena have been observed following 
ischemia in gerbils and rats. following stroke in humans, 
following administration of the toxins kainate. trimethyltin 
or colchicine in rats. and in human Alzheimer's disease. 
Several inhibitors of calpain have been described includ-
45 ing peptide aldehydes such as Ac-Leu-Leu-Nle-H and 
leupeptin (Ac-Leu-Leu-Arg-H). as well as epoxysuc-
cinates such as E-64. These compounds are not especially 
useful at inhibiting calpain in neural tissue in vivo because 
they are poorly membrane permeant and. accordingly. are 
50 not likely to cross the biood brain barrier very well. Also. 
many of these inhibitors have poor specificity and will 
inhibit a wide variety of proteases in addition to calpain. 
Other classes of compounds which inhibit cysteine proteases 
include peptide diazomethyl ketone (Rich. D. H .. in Pro-Amino acid residues and blocking groups are designated 
using standard abbreviations [see J. Biol. Chem. 260. 14-42 
(1985) for nomenclature rules; incorporated herein by 
reference]. An amino acid residue (AA) in a peptide or 
inhibitor structure refers to the part structure -NH-
CHRi--CO-. where R1 is the side chain of the amino acid 
residue AA. A peptide cx-ketoester residue would be desig-
nated -AA-CO-OR which represents the part structure 
-NH-CHR1-CO-CO-OR. Thus. the ethyl ketoester 
derived from benzoyl alanine would be designated 
Bz-Ala-CO-OEt which represents C6H5CO-NH-
CHMe-CO-CO-OEt. Peptide ketoamide residues 65 
would be designated -AA-CO-NH-R. Thus. the ethyl 
ketoamide derived from Z-Leu-Phe-OH would be des-
55 tease Inhibitors. Barrett A. I.. and Salversen. G .• Eds .. 
Elsevier. New York. 1986. pp 153-178; incorporated herein 
by reference). Peptide diazomethyl ketones are potentially 
carcinogenic and are thought to be poorly membrane per-
meant and to have low specificity. Thus, no effective therapy 
60 has yet been developed for most neurodegenerative diseases 
and conditions. Millions of individuals suffer from neuro-
degenerative diseases and thus. there is a need for therapies 
effective in treating and preventing these diseases and con-
ditions. 
Cathepsin Bis involved in muscular dystrophy. myocar-
dial tissue damage. tumor metastasis. and bone resorption. 
In addition. a number of vital processing enzymes. which are 
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essential for vital infection. are cysteine proteases. Inhibitors 
of cysteine proteases would have multiple therapeutic uses. 
4 
involved in blood coagulation are useful anticoagulants in 
vivo [see for example: H-D-Phe-Pro-Arg-CH2Cl, 
Hanson and Harker, Proc. Natl. Acad. Sci. 85, 3184-3188 
( 1988 ); 7-Arnino-4-chloro-3-(3-isothiureidopropoxy) 
Serine Proteases. Serine proteases play critical roles in 
several physiological processes such as digestion, blood 
coagulation. complement activation. fibrinolysis. vital 
infection. fertilization, and reproduction. Serine proteases 
are not only a physiological necessity, but also a potential 
hazard if they are not controlled. Uncontrolled proteolysis 
5 isocournarin (ACTI1C), Oweida. Ku, Lumsden. Karn, and 
Powers, Thrombos. Res. 58. 191-197 (1990); incorporated 
herein by reference]. 
Ketoesters. A few amino acid and peptide ketoesters and 
ketoacids have been previously reported. Cornforth and by elastases may cause. pancreatitis. emphysema, rheuma-
toid arthritis. bronchial inflammation and adult respiratory 
distress syndrome. It has been suggested that a new trypsin-
like cellular enzyme (tryptase) is involved in the infection of 
human immunodeficiency virus type 1 [HIV-1; Hattori et al., 
FEBS Letters 248, pp. 48-52 (1989)]. which is a causative 
agent of acquired immunodeficiency syndrome (AIDS). 
Plasrnin is involved in tumor invasiveness. tissue 
remodeling, blistering. and clot dissociation. Accordingly, 
specific and selective inhibitors of these proteases should be 
potent anticoagulants, anti-inflammatory agents, anti-tumor 
agents and anti-viral agents useful in the treatment of 
protease-related diseases [Powers and Harper, Proteinase 
Inhibitors, pp 55-152, Barrett and Salvesen. eds .• Elsevier. 
(1986); incorporated herein by reference]. In vitro proteoly-
10 Cornforth [J. Chem. Soc., 93-96 (1953); incorporated herein 
by reference] report the synthesis of the ketoacids 
PhCH2CO-Gly-CO-OH and Ac-Gly-CO-OH 
upon hydrolysis of heterocyclic molecules. Charles et al. [J. 
Chem. Soc. Perkin I, 139-1146 (1980); incorporated herein 
15 by reference] use ketoesters for the synthesis of bicyclic 
heterocycles. They report the synthesis of n-BuCO-
Al a-C 0-0 Et. PrCO-Ala-CO-OEt, 
cyclopentylCO-Ala-CO-OEt, PrCO-PhGly-CO-
OEt. and Bz-Ala-CO-OEt. Hori et al. [Peptides: Struc-
sis by chyrnotrypsin. trypsin or the elastase family is a 
serious problem in the production. purification, isolation, 
transport or storage of peptides and proteins. 
20 ture and Function-Proceedings of the Ninth American Pep-
tide Symposium (Deber, Hruby, and Kopple. Eds.) Pierce 
Chemical Co .• pp 819-822 (1985); incorporated herein by 
reference] report Bz-Ala-CO-OEt, Bz-Ala-CO-
OH. Z-Ala-Ala-Abu-CO-OEt, Z-Ala-Ala-
25 Abu-CO-OBz], and Z-Ala-Ala-Ala-Ala-CO-
OEt (Abu=2-aminobutanoic acid or cx-arninobutyric acid) 
and report that these compounds inhibit elastase. Trainer 
[Trends Pharm. Sci. 8. 303-307 (1987); incorporated herein 
by reference] comments on one of this compounds. 
Elastase inhibitors are anti-inflammatory agents which 
can be used to treat elastase-associated inflammation includ-
ing rheumatoid arthritis and emphysema. Although the natu-
rally occurring protease inhibitor, al-protease inhibitor ( cxl-
PI) has been used to treat patients with emphysema, this 
protein inhibitor is not widely used clinically due to the high 
dosage needed for treatment and the difficulty of producing 
large quantities. Therefore. small molecular weight elastase 
inhibitors are needed for therapy. Other low molecular 35 
weight elastase inhibitors have utility for the treatment of 
emphysema and intimation (see: 1-carpapenem-3-
carboxylic esters as anti-inflammatory agents, U.S. Pat. No. 
4,493,839; N-carboxyl-thienarnycin esters and analogs 
thereof as anti-inflammatory agents. U.S. Pat. No. 4,495, 40 
197; incorporated herein by reference). 
30 Burkhart, J., Peet, N. P .. and Bey, P. [Tetrahedron Left. 29, 
3433-3436 (1988); incorporated herein by reference] report 
the synthesis of Z-Val-Phe-CO-OMe and Bz-Phe-
CO-OMe. 
Anticoagulants and antithrombotic drugs are used in a 
variety of thrombotic disorders. The 1990 Physician's Desk 
Reference lists several anticoagulant drugs (heparin. prota-
rnine sulfate and warfarin). a few antiplatelet drugs (aspirin) 45 
and several thrombolytic agents. Herring and warfarin are 
commonly used clinically for prevention and treatment of 
venous thrombosis and pulmonary embolism. Heparin 
inhibits the blood coagulation activity by accelerating the 
binding of natural plasma protease inhibitor antithrombin m 50 
with coagulation factors, and warfarin acts as a vitamin K 
antagonist and inhibits the synthesis of coagulation factors. 
None of the anticoagulant drugs, antithrombotic drugs, 
fibrolytic agents and antiplatelet drags are highly effective in 
all clinical situations and many induce side reactions [Von 55 
Kaulla, Burger's Medicinal Chemistry, Part II. pp 
1081-1132. Wolff, ed., (1979); incorporated herein by 
reference]. Coagulation disorders such as disseminated 
intravascular coagulation, bleeding complications of medi-
cal and surgical procedures and bleeding complications of 60 
systemic illness are still difficult to manage [Ingram, Bro-
zovic and Slater. Bleeding Disorders, pp 1-413. Blackwell 
Scientific Publications, (1982); incorporated herein by 
reference]. In the treatment of patients with coagulation 
problems. anticoagulant or antithrombotic agents of diverse 65 
mechanisms are urgently sought in order to provide better 
medical care. Inhibitors for the trypsin-like enzymes 
Mehdi et al.. [Biochem. Biophys. Res. Comm. 166, 
595-600 (1990); incorporated herein by reference] report 
the inhibition of human neutrophil elastase and cathepsin G 
by peptide cx-ketoesters. Angelastro et al., [J. Med. Chem. 
33. 13-16 (1990); incorporated herein by reference] report 
some cx-ketoesters which are inhibitors of calpain and chy-
motrypsin. Hu and Abeles [Arch. Biochem. Biophys. 281. 
271-274 (1990)]; incorporated herein by reference] report 
some peptidyl cx-ketoarnides and cx-ketoacids which are 
inhibitors of cathepsin B and papain. Peet et al. [J. Med. 
Chem. 33. 394-407 (1990); incorporated herein by 
reference] report some peptidyl cx-ketoesters which are 
inhibitors of porcine pancreatic elastase, human neutrophil 
elastase. and rat & human neutrophil cathepsin G. 
Ketoarnides. A single peptide ketoarnide is reported in the 
literature by Hu and Abeles [Arch. Biochem. Biophys. 281, 
271-274 (1990)]. This compound Z-Phe-NHCH2CO-
CO-NH-Et or Z-Phe-Gly-CO-NH-Et is reported 
to be an inhibitor of papain (Ki=l.5 µM) and cathepsin B 
(Kr=4 µM). 
SUMMARY OF THE INVENTION 
We have discovered that peptide and amino acid 
cx-ketoarnide derivatives are a novel group of inhibitors for 
serine proteases and cysteine proteases. Inhibitors are com-
pounds that reduce or eliminate the catalytic activity of the 
enzyme. We have discovered that peptide ketoarnide 
derivatives, which have an amino acid sequence similar to 
that of good substrates for a particular protease, are good 
inhibitors for that protease. Thus. we are able to predict the 
structures of new inhibitors for other serine and cysteine 
proteases based on knowledge of their substrate specificities. 
We have discovered some peptide cx-ketoarnide deriva-
tives which are specific inhibitors for chyrnotrypsin. Chy-
5,650,508 
5 
motrypsin and chymotrypsin-like enzymes hydrolyze pep-
tide bonds where P 1 amino acid is Trp. 1)7r. Phe, Met. Leu 
6 
chymotrypsin. trypsin and related serine proteases. These 
inhibitors may be used in vitro to prevent proteolysis which 
occurs in the process of production. isolation. purification. 
storage or transport of peptides and proteins. These inhibi-
or other amino acid residues which contain aromatic or large 
alkyl side chains. Inhibitors with these residues at P 1 are 
good chymotrypsin and chymase inhibitors. Trypsin and 
trypsin-like enzymes normally cleave peptide bonds in pro-
teins and peptides where the amino acid residue on the 
carbonyl side of the split bond (P 1 residue) is Lys or Arg. We 
show that peptide a-ketoamide derivatives which have Lys 
5 tors may be useful as therapeutic agents for treatment of 
neurodegeneration. viral infections. muscular dystrophy. 
myocardial tissue damage. tumor metastasis. and bone 
resorption. 
The novel class of dipeptide a-ketoamides have the 
10 following structural formula: or Arg at P 1 will be good inhibitors for these enzymes. 
Elastase and elastase-like enzymes cleave peptide bonds 
where the P 1 amino acid is Ala. Val, Set, Leu and other 
similar amino acids. We shown that inhibitors with these 
residues at P1 are good elastase inhibitors. All of the above 
enzymes have extensive secondary specificity and recognize 15 
amino acid residues removed from the P 1 residue. 
The peptide a-ketoamide derivatives are also novel and 
potent inhibitors of cysteine proteases including calpains 
and cathepsin B. The calpain inhibitors are useful for 
treatment of various neurodegenerative diseases and 20 
conditions. including ischemia. stroke, and Alzheimer's 
disease. 
The new protease inhibitors. especially the elastase 
inhibitors, trypsin inhibitors, and chymase inhibitors are 
useful for controlling tissue damage and various inflamma- 25 
tory conditions mediated by proteases such as blistering. The 
inhibitors for blood coagulation enzymes will be useful 
anticoagulants and could be used to treat thrombosis. 
The peptide and amino acid a-ketoamide derivatives are 30 
also useful in vitro for inhibiting trypsin. elastase. chymot-
rypsin and other serine proteases of similar specificity. and 
for inhibiting serine proteases in general. The inhibitors can 
be used to identify new proteolytic enzymes encountered in 
research. They can also be used in research and industrially 35 
to prevent undesired proteolysis that occurs during the 
production, isolation. purification, transport and storage of 
valuable peptides and proteins. Such proteolysis often 
destroys or alters the activity and/or function of the peptides 
and proteins. Uses would include the addition of the inhibi- 40 
tors to antibodies. enzymes, plasma proteins. tissue extracts 
or other proteins and peptides which are widely sold for use 
in clinical analyses. biomedical research. and for many other 
reasons. For some uses a specific inhibitor would be 
desirable. while in other cases, an inhibitor with general 45 
specificity would be preferred. 
DETAILED DESCRIPTION OF THE 
JNVENTION 
Peptide a-ketoamides are transition state analog inhibi- 50 
tors for serine proteases and cysteine proteases. Peptide 
a-ketoamides containing hydrophobic amino acid residues 
in the P 1 site have been found to be excellent inhibitors of 
serine proteases including porcine pancreatic elastase and 
bovine chymotrypsin. We show that peptide a-ketoamides 55 
containing amino acid residues with cationic side chains in 
the P 1 site will be excellent inhibitors of several serine 
proteases including bovine trypsin. bovine thrombin, human 
plasma kallikrein. porcine pancreatic kallikrein. human fac-
tor Xia and human plasmin. Peptide a-ketoamides contain- 60 
ing amino acid residues with hydrophobic side chain at the 
P 1 site have also been found to be excellent inhibitors of 
several cysteine proteases including papain. cathepsin B. 
calpain I. and calpain II. These structures may be used in 
vivo to treat diseases such as emphysema. adult respiratory 65 
distress syndrome. rheumatoid arthritis and pancreatitis 
which result from uncontrolled proteolysis by elastase. 
M 1-AA-NH-CHR2---CO---CO-NR3R4 
or a pharmaceutically acceptable salt. wherein 
M1 represents H. NH2--CO-. NH2-CS-. NH2-
S02-, X-NH-CO-. X2N-CO-. X-NH-
CS-. X2N--CS-. X-NH-S02-. X2N-S02-. 
X-CO-. X-CS-. X-S02-. X-0--CO-. or 
X-0--CS-; 
x is selected from the group consisting of cl-10 alkyl. 
C1_10 :fiuoroalkyl. C1_10 alkyl substituted with J. C1_10 
:fiuoroalkyl substituted with I. 1-admantyl. 9-:fiuorenyl. 
phenyl. phenyl substituted with K. phenyl disubstituted 
with K. phenyl trisubstituted with K. naphthyl. naph-
thyl substituted with K. naphthyl disubstituted with K. 
naphthyl trisubstituted with K. C1_10 alkyl with an 
attached phenyl group. C1_10 alkyl with two attached 
phenyl groups. cl-10 alkyl with an attached phenyl 
group substituted with K. C1_10 alkyl with two attached 
phenyl groups substituted with K. cl-10 alkyl with an 
attached phenoxy group. and cl-10 alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen. COOH. 
OH. CN. N02. NH2• C1_10 alkoxy. C1_10 alkylamine. 
C2_12 dialkylarnine. C1_10 alkyl-0-CO-. C 1_10 
alkyl-0--CO-NH-. and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen. C1_10 
alkyl. C1_10 per:fiuoroalkyl. C1_10 alkoxy. N02, CN. 
OH. C02H. amino. C 1_10 alkylamino. C 2_12 
dialkylamino. Ci-C10 acyl. and C1_10 alkoxy-CO-. 
and C1_10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid with 
the L configuration. D configuration. or no chirality at 
the a-carbon selected from the group consisting of 
alanine. valine. leucine. isoleucine, proline. 
methionine. methionine sulfoxide, phenylalanine. 
tryptophan. glycine. serine, threonine, cysteine. 
tyrosine. asparagine. glutamine. aspartic add. glutamic 
acid, lysine. arginine, histidine, phenylglycine, beta-
alanine, norleucine, norvaline, alpha-aminobutyric 
acid. epsilon-aminocaproic acid. citrulline, 
hydroxyproline, ornithine. homoarginine. sarcosine. 
indoline 2-carboxylic acid, 2-azetidinecarboxylic acid. 
pipecolinic acid (2-piperidine carboxylic acid). 
0-methylserine. 0-ethylserine, S-methylcysteine. 
S-ethylcysteine. S-benzylcysteine, NH2-CH 
(CH2CHEt2)-COOH, alpha-aminoheptanoic acid, 
NH2--CH(CH2- l-napthyl)-COOH. NH2--CH(CH2-2-
napthy l)-COOH. NH 2-CH(CH2-cyclohexyl)-
COOH. NH2--CH(CH2-cyclopentyl)-COOH. NH2-
CH(CH2-cyclobutyl)-COOH. NH 2-CH(CH2-
cyclopropyl)-COOH. tri:fiuoroleucine, and 
hexa:fiuoroleucine; 
R2 is selected from the group consisting of C1-a branched 
and unbranched alkyl. C1_8 branched and unbranched 
cyclized alkyl. and cl-8 branched and unbranched 
:fiuoroalkyl; 
5,650,508 
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R3 and R4 are selected independently from the group 
consisting of H, cl-20 alkyl, c3-20 cyclized alkyl. cl-20 
alkyl with a phenyl group attached to the cl-20 alkyl, 
c3-20 cyclized alkyl with an attached phenyl group. 
cl-20 alkyl with an attached phenyl group substituted 5 
with K. C1_20 alkyl with an attached phenyl group 
disubstituted with K. cl-20 alkyl with an attached 
phenyl group trisubstituted with K. C3_20 cyclized alkyl 
with an attached phenyl group substituted with K. cl-10 
alkyl with a morpholine [-N(CH2CH2)0] ring 10 
attached through nitrogen to the alkyl, cl-10 alkyl with 
a piperidine ring attached through nitrogen to the alkyl, 
C1_10 alkyl with a pyrrolidine ring attached through 
nitrogen to the alkyl, C1_20 alkyl with an OH group 
attached to the alkyl, -CH2CH20CH2CH20H. C1_10 15 
with an attached 4-pyridyl group. cl-10 with an 
attached 3-pyridyl group. C1_10 with an attached 
2-pyridyl group. cl-10 with an attached cyclohexyl 
group. -NH-CH2CH2-(4-hydroxyphenyl). and 
-NH-CH2CH2-(3-indolyl). 20 
The novel class of dipeptide a-ketoamides also have the 
following structural formula: 
M1-AA2-AA1--CO-NR3R4 
or a pharmaceutically acceptable salt, wherein 
25 
M 1 represents H, NH2-CO-. NH2-CS-. NH2-
S02-, X-NH-CO-. X2N-CO-. X-NH-
CS-. X2N-CS-. X-NH-S02-. X2N-S02-, 
X-CO-. X-CS-. X-S02-. X-0--CO-, or 30 
X-0--CS-; 
x is selected from the group consisting of cl-10 alkyl, 
C1_10 fiuoroalkyl, C1_10 alkyl substituted with J. C1_10 
fiuoroalkyl substituted with J, 1-adrnantyl, 9-fiuorenyl, 35 phenyl, phenyl substituted with K. phenyl disubstituted 
with K. phenyl trisubstituted with K, naphthyl, naph-
thyl substituted with K. naphthyl disubstituted with K. 
naphthyl trisubstituted with K. C1_10 alkyl with an 
attached phenyl group. C1_10 alkyl with two attached 40 phenyl groups. cl-10 alkyl with an attached phenyl 
group substituted with K. C1_10 alkyl with two attached 
phenyl groups substituted with K. C1_10 alkyl with an 
attached phenoxy group. and C1_10 alkyl with an 
attached phenoxy group substituted with K on the 
45 phenoxy group; 
J is selected from the group consisting of halogen, COOH, 
OH. CN. N02, NH2, C1_10 alkoxy, C1_10 alkylamine, 
C2_12 dialkylamine, C1_10 alkyl-0--CO-. C1_10 alkyl-
0-CO-NH-. and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfioroalkyl, C1_10 alkoxy. N02• CN. OH. 
C02H, amino, C1_10 alkyl amino, C2_12 dialkylamino. 
C1-C10 acyl, and C1_10 alkoxy-CO-. and C1_10 alkyl-
S-; 
50 
55 
AA1 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine. praline. 
methionine, methionine sulfoxide. phenylalanine, 60 
tryptophan, serine, threonine, cysteine. tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid. 
lysine. arginine, histidine. phenylglycine, beta-alanine. 
norleucine, norvaline, alpha-aminobutyric acid, 
epsilon-aminocaproic acid, citrulline, hydroxyproline. 65 
ornithine. homoarginine, sarcosine, indoline 
2-carboxylic acid. 2-azetidinecarboxylic acid. pipe-
8 
colinic acid (2-piperidine carboxylic acid), 
0-methylserine. 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH 2-CH 
(CH2CHEt2)-COOH. alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-2-
napthyl)-COOH. NH2-CH(CH2-cyclohexyl)-COOH. 
NH2-CH(CH2-cyclopentyl)-COOH, NH2-CH(CH2-
cyclobutyl)-COOH. NH2-CH(CH2-cyclobutyl)-
COOH. NH 2-CH(CH2-cyclopropyl)-COOH. 
trifiuoroleucine. and hexafiuoroleucine; 
AA2 is a side chain blocked or unblocked amino acid with 
the L configuration. D configuration, or no chirality at 
the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, 
methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine. threonine, cysteine, 
tyrosine. asparagine. glutarnine, aspartic acid, glutamic 
acid, lysine. arginine. histidine. phenylglycine, beta-
alanine. norleucine, norvaline. alpha-aminobutyric 
acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline. ornithine, homoarginine, sarcosine, 
indoline 2-carboxylic acid, 2-azetidinecarboxylic acid, 
pipecolinic acid (2-piperidine carboxylic acid), 
0-methylserine, 0-ethylserine. S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine. NH2-CH 
(CH2CHEt2)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-2-
napthyl)-COOH. NH2-CH)CH2-cyclohexyl) -COOH, 
NH2-CH(CH2-cyclopentyl)-COOH. NH2-CH(CH2-
cyclobutyl)-COOH. NH2-CH(CH2-cyclopropyl)-
COOH. trifiuoroleucine, and hexafiuoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H. C1_20 alkyl, C3_20 cyclized alkyl, C1_20 
alkyl with a phenyl group attached to the cl-20 alkyl, 
c3-20 cyclized alkyl with an attached phenyl group, 
C1_20 alkyl with an attached phenyl group substituted 
with K. C1_20 alkyl with an attached phenyl group 
disubstituted with K. cl-20 alkyl with an attached 
phenyl group trisubstituted with K. c3-20 cyclized alkyl 
with an attached phenyl group substituted with K. cl-10 
alkyl with a morpholine [-N(CH2CH2)0] ring 
attached through nitrogen to the alkyl, C1_10 alkyl with 
a piperidine ring attached through nitrogen to the alkyl, 
cl-10 alkyl with a pyrrolidine ring attached through 
nitrogen to the alkyl, C1_20 alkyl with an OH group 
attached to the alkyl, -CH2CH20CH2CH20H, C1_10 
with an attached 4-pyridyl group. C1_10 with an 
attached 3-pyridyl group. cl-10 with an attached 
2-pyridyl group, C1_10 with an attached cyclohexyl 
group, -NH-CH2CH2-(4-hydroxyphenyl), and 
-NH-CH2CH2-(3-indolyl). 
The novel class of tripeptide a-ketoamides have the 
following structural formula: 
M 1-AA-AA-AA--CO-NR3R4 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, NH2-
S02-. X-NH-CO-, X2N-CO-, X-NH-
CS-. X2N-CS-. X-NH-S02-. X-S02-, 
X-CO-, X-CS-. X-S02-. X-0-CO-, or 
X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
C1_10 fiuoroalkyl, C1_10 alkyl substituted with J. C1_10 
fiuoroalkyl substituted with J. 1-admantyl, 9-fiuorenyl, 
phenyl, phenyl substituted with K. phenyl disubstituted 
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with K. phenyl trisubstituted with K. naphthyl. naph-
thyl substituted with K. naphthyl disubstituted with K. 
naphthyl trisubstituted with K. cl-10 alkyl with an 
attached phenyl group. C1_10 alkyl with two attached 
phenyl groups. cl-10 alkyl with an attached phenyl 5 
group substituted with K. cl-10 alkyl with two attached 
phenyl groups substituted with K. C1_10 alkyl with an 
attached phenoxy group. and cl-10 alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 10 
J is selected from the group consisting of halogen, COOR. 
OH. CN. N02, NH2• C1_10 alkoxy. C1_10 alkylamine. 
C2_12 dialkylamine, C1_10 alkyl-0--CO-. C1_10 all.-yl-
0--CO-NH-. and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen. C1_10 
15 
alkyl. C1_10 perfluoroalkyl. C1_10 alkoxy. N02• CN. 
OH. C0 2H. amino. C1_10 alkylamino. C 2_12 
dialkylamino. C1_10 acyl. and C1_10 alkoxy-CO-. and 
C1_10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid with 20 
the L configuration. D configuration. or no chirality at 
the a-carbon selected from the group consisting of 
alanine. valine. leucine. isoleucine. proline. 
methionine. methionine sulfoxide. phenylalanine. 25 
tryptophan. glycine. serine, threonine. cysteine. 
tyrosine. asparagine. glutamine, aspartic acid, glutamic 
acid. lysine. arginine, histidine. phenylglycine. beta-
alanine. norleucine. norvaline. alpha-aminobutyric 
acid. epsilon-aminocaproic acid. citrulline, 30 hydroxyproline. ornithine. homoarginine. sarcosine. 
indoline 2-carboxylic acid. 2-azetidinencarboxylic 
acid. pipecolinic acid (2-piperidine carboxylic acid), 
0-methylserine, 0-ethylserine. S-methylcysteine. 
S-ethylcysteine. S-benzylcysteine. NH2-CH 35 (CH2CHEt2)-COOH. alpha-aminoheptanoic acid. 
NH2--CH(CH2-l-napthyl)-COOH. NH2--CH(CH2_2-
napthyl)-COOH. NH2-CH(CH2-cyclohexyl)-COOH. 
NH2--CH(CH2-cyclopentyl)-COOH. NH2-CH(CH2-
cyclobutyl)-COOH. NH2-CH(CH2-cyclopropyl)- 40 COOH. trifluoroleucine. and hexafiuoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H. C1_20 alkyl. C3_20 cyclized alkyl, C1_20 
alkyl with a phenyl group attached to the cl-20 alkyl. 
c3-20 cyclized alkyl with an attached phenyl group. 45 
cl-20 alkyl with an attached phenyl group substituted 
with K. C1_20 alkyl with an attached phenyl group 
disubstituted with K. C1_20 alkyl with an attached 
phenyl group trisubstituted with K. c3-20 cyclized alkyl 
with an attached phenyl group substituted with K. cl-10 50 
alkyl with a morpholine [-N(CH2CH2)0] ring 
attached through nitrogen to the alkyl. C1_10 alkyl with 
a piperidine ting attached through nitrogen to the alkyl. 
cl-10 alkyl with a pyrrolidine ring attached through 
nitrogen to the alkyl. C1_20 alkyl with an OH group 55 
attached to the alkyl. --CH2CH20CH2CH20H. C1_10 
with an attached 4-pyridyl group. C1_10 with an 
attached 3-pyridyl group. cl-10 with an attached 
2-pyridyl group. cl-10 with an attached cyclohexyl 
group. -NH-CH2CH2-(4-hydroxyphenyl). and 60 
-NH--CH2CH2-(3-indolyl). 
The novel class of tetrapeptide a-ketoamides have the 
following structural formula: 
M 1-AA-AA-AA-AA--<:.O-NR3 R4 
or a pharmaceutically acceptable salt. wherein 
65 
10 
M1 represents H. NH2--CO-. NH2--CS-. NH2-
S02-. X-NH-CO-. X2N-CO-. X-NH-
CS-. X2N--CS-. X-NH-S02-. X2N--S02-. 
X-CO-. X-CS-. X--S02-. X-0-CO-. or 
X-0--CS-; 
X is selected from the group consisting of C1_10 alkyl. 
C1_10 fluoroalkyl. C1_10 alkyl substituted with J. C1_10 
fluoroalkyl substituted with J. 1-adrnantyl. 9-fluorenyl. 
phenyl. phenyl substituted with K. phenyl disubstituted 
with K. phenyl trisubstituted with K. naphthyl. naph-
thyl substituted with K. naphthyl disubstituted with K. 
naphthyl trisubstituted with K. cl-10 alkyl with an 
attached phenyl group. cl-10 alkyl with two attached 
phenyl groups. cl-10 alkyl with an attached phenyl 
group substituted with K. C1_10 alkyl with two attached 
phenyl groups substituted with K. C1_10 alkyl with an 
attached phenoxy group. and cl-10 alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen. COOH. 
OH. CN. N02• NH2. C1_10 alkoxy. C1_10 alkylamine. 
C2_12 dialkylamine. C1_10 alkyl-0--CO-. C1_10 alkyl-
0--CO-NH-. and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen. C Ho 
alkyl. C1_10 perfluoroalkyl. C1_10 alkoxy. N02• CN. 
OH. C02H. amino. C1_10 alkylarnino. C2_12 
dialkylamino. C1_10 acyl. and C1_10 alkoxy-CO-. and 
C1-10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid with 
the L configuration. D configuration. or no chirality at 
the a-carbon selected from the group consisting of 
alanine. valine. leucine. isoleucine. proline. 
methionine. methionine sulfoxide, phenylalanine, 
tryptophan. glycine. serine, threonine. cysteine. 
tyrosine. asparagine. glutamine, aspartic acid, glutamic 
acid. lysine. arginine. histidine, phenylglycine. beta-
alanine. norleucine. norvaline. alpha-aminobutyric 
acid. epsilon-aminocaproic acid, citrulline. 
hydroxyproline. ornithine, homoarginine. sarcosine. 
indoline 2-carboxylic acid, 2-azetidinecarboxylic acid. 
pipecolinic acid (2-piperidine carboxylic acid). 
0-methylserine. 0-ethylserine. S-methylcysteine, 
S-ethylcysteine. S-benzylcysteine, NH2-CH 
(CH2CHEt2)-COOH. alpha-arninoheptanoic acid, 
NH2--CH(CH2-l-napthyl)-COOH, NH2-CH(CH2-2-
napthyl)-COOH. NH2-CH(CH2-cyclohexyl)-COOH. 
NH2--CH(CH2-cyclopentyl)-COOH. NH2--CH(CH2-
cyclobutyl)-COOH. NH2--CH(CH2-cyclopropyl)-
COOH. trifluoroleucine, and hexafiuoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H. C1_20 alkyl. C3_20 cyclized alkyl. C1_20 
alkyl with a phenyl group attached to the C1_20 alkyl. 
c3-20 cyclized alkyl with an attached phenyl group, 
cl-20 alkyl with an attached phenyl group substituted 
with K. cl-20 alkyl with an attached phenyl group 
disubstituted with K. C1_20 alkyl with an attached 
phenyl group trisubstituted with K. cl-20 cyclized alkyl 
with an attached phenyl group substituted with K. C1_10 
alkyl with a morpholine [-N(CH2CH2)0] ring 
attached through nitrogen to the alkyl. cl-10 alkyl with 
a piperidine ting attached through nitrogen to the alkyl. 
C1_10 alkyl with a pyrrolidine ring attached through 
nitrogen to the alkyl. C1_20 alkyl with an OH group 
attached to the alkyl. --CH2CH20CH2CH20H. C1_10 
with an attached 4-pyridyl group. C1_10 with an 
attached 3-pyridyl group. C1_10 with an attached 
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2-pyridyl group, C1_10 with an attached cyclohexyl 
group, -NH-CH2 CH2-(4-hydroxyphenyl), and 
-NH--CH2CH2-(3-indolyl). 
The novel class of amino acid a-ketoamides have the 
following structural formula: 
or a pharmaceutically acceptable salt, wherein 
5 
M1 represents H, NH2-CO-, NH2-CS-, NH2- 10 
S02-, X-NH-CO-, X2N-CO-, X-NH-
CS-, X2N--CS-, X-NH-S02-, X2N-S02-, 
X--CO-, X-CS-. X-S02-, X-0--CO-, or 
X-0--CS-; 
X is selected from the group consisting of C1_10 alkyl. 
15 
C1_10 fiuoroalkyl. C1_10 alkyl substituted with J, C1_10 
fiuoroalkyl substituted with J, 1-admantyl. 9-fiuorenyl. 
phenyl. phenyl substituted with K, phenyl disubstituted 
with K, phenyl trisubstituted with K. naphthyl, naph-
20 thyl substituted with K. naphthyl disubstituted with K. 
naphthyl trisubstituted with K. C1_10 alkyl with an 
attached phenyl group, C1_10 alkyl with two attached 
phenyl groups, C1_10 alkyl with an attached phenyl 
group substituted with K. C1_10 alkyl with two attached 25 phenyl groups substituted with K. C1_10 alkyl with an 
attached phenoxy group, and C1_10 alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, COOH, 30 OH, CN, N02, NH2. C1_10 alkoxy, C1_10 alkylarnine, 
C2_12 dialkylarnine, C1_10 alkyl-0--CO-, C1_10 alkyl-
0-CO-NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl. C1_10 perfioroalkyl, C1_10 alkoxy, N02• CN, OH, 35 
C02H, amino, C1_10 alkylarnino, C2_12 dialkylarnino, 
C1_10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-
S-; 
12 
phenyl group trisubstituted with K. c3-20 cyclized alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with a morpholine [-N(CH2CH2)0] ring 
attached through nitrogen to the alkyl. C1_10 alkyl with 
a piperidine ring attached through nitrogen to the alkyl. 
C1_10 alkyl with a pyrrolidine ring attached through 
nitrogen to the alkyl. C1_20 alkyl with an OH group 
attached to the alkyl. --CH2CH20CH2CH20H, C1_10 
with an attached 4-pyridyl group, C1_10 with an 
attached 3-pyridyl group, Cl.10 with an attached 
2-pyridyl group. C1_10 with an attached cyclohexyl 
group, -NH--CH2CH2-(4-hydroxyphenyl), and 
-NH--CH2 CH2-(3-indolyl). 
The following compounds are representatives of the 
invention: 
Z-Leu-Phe--CONH-Et 
Z-Leu-Phe-CONH-nPr 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH-(CHi)jlh 
Z-Leu-Abu--CONH-Et 
Z-Leu-Abu--CONH-nPr 
Z-Leu-Abu--CONH-nBu 
Z-Leu-Abu--CONH-iBu 
Z-Leu-Abu--CONH-Bzl 
Z-Leu-Abu--CONH-(CH2hPh 
Z-Leu-Abu--CONH-(CH2h-N(CH2CHi)20 
Z-Leu-Abu--CONH-(CH2hCH3 
Z-Leu-Abu--CONH-(CH2)20H 
Z-Leu-Abu--CONH-(CH2hO(CH2)iOH 
Z-Leu-Abu--CONH-(CH2)17CH3 
Z-Leu-Abu--CONH:--CH2--C6H3(0CH3h 
Z-Leu-Abu--CONH--CH2--C4H4N 
Materials and Methods. HEPES, heparin, and A23187 
were obtained from Calbiochem. Suc-Leu-Tyr-AMC 
and chromogenic substrates were obtained from Sigma. 
Calpain I was purified from human erythrocytes according 
to the method of Kitahara (Kitahara et al., J. Biochem. 95, 
1759-1766) omitting the Blue-Sepharose step. Calpain II 
from rabbit muscle and cathepsin B were purchased from 
Sigma. Papain was purchased from Calbiochem. 
Assay of Inhibitory Potency. Peptide a-ketoamides were 
assayed as reversible enzyme inhibitors. Various concentra-
tions of inhibitors in Me2SO were added to the assay mixture 
which contained buffer and substrate. The reaction was 
started by the addition of the enzyme and the hydrolysis 
rates were followed spectrophotometrically or fiuorimetri-
cally. 
Calpain I from human erythrocytes and calpain II from 
rabbit were assayed using Suc-Leu-Tyr-AMC [Sasaki 
et al., J. Biol. Chem. 259, 12489-12494 (1984); incorporated 
herein by reference], and the AMC (7-amino-4-
methylcoumarin) release was followed fiuorimetrically 
(excitation at 380 nm, and emission at 460 nm). Calpains 
were assayed in 25 mM Tris pH=8.0, 10 mM CaC12. 
Fluorescence was followed using a Gilson FL-lA fiuorom-
eter or a Perkin-Elmer 203 Fluorescence spectrometer. 
Cathepsin B was assayed in 20 rnM sodium acetate pH=5.2, 
AA is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 40 
the a-carbon selected from the group consisting of 
alanine, valine. leucine, isoleucine, proline, 
methionine, methionine sulfoxide, phenylalanine, 
tryptophan. glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glum mine, aspartic acid, 45 
glutamic acid, lysine, arginine, histidine, 
phenylglycine, beta-alanine, norleucine, norvaline, 
alpha-arninobutyric acid. epsilon-aminocaproic acid, 
citrulline, hydroxyproline, ornithine, homoarginine, 
sarcosine, indoline 2-carboxylic acid, 50 
2-azetidinecarboxylic acid, pipecolinic acid 
(2-piperidine carboxylic acid), 0-methylserine, 
0-ethylserine, S-methylcysteine, S-ethylcysteine, 
S-benzylcysteine, NH2--CH(CH2 CHEt2)-COOH. 
alpha-aminoheptanoic acid, NH2-CH(CH2-l- 55 
napthyl)-COOH, NH2--CH(CH2-2-napthyl)-COOH, 
NH2--CH(CH2-cyclohexyl)-COOH, NH2--CH(CH2-
cyclopentyl)-COOH, NH2-CH(CH2-cyclobutyl)-
COOH, NH 2-CH(CH2-cyclopropyl)-COOH, 
trifiuoroleucine, and hexafiuoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H. C1_20 alkyl. C3_20 cyclized alkyl. C1-20 
alkyl with a phenyl group attached to the c!-20 alkyl. 
c3-20 cyclized alkyl with an attached phenyl group, 
C1_20 alkyl with an attached phenyl group substituted 65 
with K. C1_20 alkyl with an attached phenyl group 
disubstituted with K. C1_20 alkyl with an attached 
60 0.5 rnM dithiothreitol using Bz-Phe-Val-Arg-p-
nitroanilide as substrate. Alternately, cathepsin B was 
assayed with Z-Arg-Arg-AFC [Barrett and Kirschke, 
Methods Enzymol. 80, 535-561 (1981); incorporated herein 
by reference], and the AFC (7-amino-4-
trifiuoromethylcoumarin) release was followed fiuorimetri-
cally (excitation at 400 nm and emission at 505 nm). Papain 
was assayed in 100 mM KP04 , 1 mM EDTA. 2.5 rnM 
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Samples were subjected to SDS-PAGEin 4-12% gradient 
mini gels (Novex) and transferred to nitrocellulose 
(Schleicher and Schuell 0.45 um) by electroblotting. Filters 
were blocked for 10 minutes in 0.25% gelatin. 1 % BSA. 
cysteine pH=6.0 using Bz-Arg-AMC or Bz-Arg-NA 
[Kanaoka et al .. Chem. Pharm. Bull. 25. 3126-3128 (1977); 
incorporated herein by reference] as a substrate. The AMC 
(7-arnino-4-methylcoumarin) release was followed fiuori-
metrically (excitation at 380 nm, and emission at 460 nm). 
Enzymatic hydrolysis rates were measured at various sub-
strate and inhibitor concentrations. and K1 values were 
determined by either Lineweaver-Burk plots or Dixon plots. 
A O.lM Hepes. 0.5M NaCl. pH 7.5 buffer was utilized for 
human leukocyte elastase (HLE). porcine pancreatic elastase 
(PPB). chyrnotrypsin and cathepsin G. A 0.1 Hepes. O.OlM 
CaCl2• pH 7.5 buffer was utilized for trypsin. plasmin. and 
coagulation enzymes. A 50 rnM Tris.HCI. 2 rnM EDTA. 5 
rnM cysteine, pH 7 .5 was used as a buffer for papain. A 88 
rnM KHzl'04. 12 rnM Na2HP04 , 1.33 rnM EDTA. 2.7 mm 
cysteine. pH 6.0 solution was used as a buffer for cathepsin 
B. A 20 rnM Hepes, 10 rnM CaC12• 10 rnM mercatoethanol. 
5 0.25% triton X100. 0 _9% NaCl. 10 rnM Tris-Cl pH 7.5. 
incubated overnight in the same solution containing anti-
body to rat spectrin. washed 3x10 minutes with 10 rnM 
Tris-Cl pH 7 .5. 0.5% triton X 100. incubated 4 hours in wash 
buffer plus alkaline phosphatase conjugated goat anti-rabbit 
10 antibody (Biorad), and washed as above. Blots were devel-
oped using the Biorad AP conjugate substrate kit. Quanti-
tative densitometry was used to obtain values for the intact 
spectrin bands and the 150/155 kDa breakdown product 
doublet. 
15 Structure-Activity Relationships. Table I shows the inhi-
bition constants (K1) for cathepsin B. calpain L and calpain 
II. Dipeptide a-ketoamides with Abu and Phe in the P 1 site 
and Leu in the P 2 site are potent inhibitors of calpain I and 
calpain IL Z-Leu-Abu--CONH-Et is a better inhibitor 
pH 7 .2 buffer was utilized for calpain I and calpain II. 
HLE and PPB were assayed with MeO-Suc-Ala-
Ala-Pro-Val-NA and Sue-Ala-Ala-Ala-NA. 
respectively [Nakajima et al.. J. Biol. Chem. 254. 
4027-4032 (1979); incorporated herein by reference]. 
Human leu.kocyte cathepsin G and chyrnotrypsin Aa. were 
assayed with Suc-Val-Pro-Phe-NA [Tanaka et al .• 
Biochemistry 24. 2040-2047 (1985); incorporated herein by 
reference]. The hydrolysis of peptide 4-nitroanilides was 
measured at 410 nm [e410=8800 M-1 cm-1; Erlanger et al .. 
Arch. Biochem. Biophys. 95. pp 271-278 (1961); incorpo-
rated herein by reference]. Trypsin, thrombin. human plasma 
kallikrein. porcine pancreatic kallikrein. human factor XIa. 
and human plasmin were assayed with Z-Arg--SBzl or 
Z-Gly-Arg-SBu-i [McRae et al.. Biochemistry 20, 
7196-7206 (1981); incorporated herein by reference]. All 
peptide thioester hydrolysis rates were measured with assay 
mixtures containing 4.4'-dithiodipyridine [e324=19800 M-1 
cm-1 ; Grasetti & Murray. Arch. Biochem. Biophys. 119, 
41-49 (1967); incorporated herein by reference]. 
20 of calpain I than Z-Leu-Phe-CONH-Et by 14 fold. 
Replacement of the Z group (PhCH20CO-) by similar 
groups such as PhCH2CH2CO-. PhCH2CH2S02-, 
PhCHzNHCO-. and PhCH2NHCS- would also result in 
good inhibitor structures. The best inhibitor of calpain II is 
25 Z-Leu-Abu-CONH-(CH2)z-Ph. Changing the R3 
and R4 groups significantly improves the inhibitory potency 
toward calpain II. The best dipeptide inhibitors are those 
which have long alkyl side chains (e.g. Z-Leu-Abu-
CONH-(CH2hCH3), alkyl side chains with phenyl substi-
30 tuted on the alkyl group (e.g. Z-Leu-Abu--CONH-
(CH~2-Ph). or alkyl groups with a morpholine ring 
substituted on the alkyl group [e.g. Z-Leu-Abu-
CONH-(CH2)3-Mpl. Mpl=-N(CH2CH2h0 ]. Dipeptide 
a-ketoamides with a small aliphatic amino acid residue or a 
35 Phe in the P1 site are also good inhibitors for cathepsin B. 
The best inhibitor is Z-Leu-Abu--CONH-Et and 
replacement of the Z (PhCH20CO-) by PhCH2CH2CO-. 
PhCH2CH2S02-. PhCHzNHCO-. and PhCHzNHCS-
would also result in good inhibitor structures. 
Platelet membrane permeability assay. Calpain-mediated 
breakdown of spectrin was measured by quantitative densi-
tometry of the calpain-speci:fic 150/155 kDa spectrin frag- 40 
ment doublet [see Siman et al .. Proc. Natl. Acad. Sci. USA 
81. 3572-3576 (1984)]. Platelets were isolated by a modi-
fication of the method of Ferrell and Martin [J. Biol. Chem. 
264, 20723-20729 (1989)]. Blood (15-20 ml) was drawn 
from male Sprague-Dawley rats into V1oth volume of 100 45 
rnM EDTA-citrate, and centrifuged 10 minutes at 2000 rpm 
in a clinical centrifuge at room temperature. The plasma was 
resuspended in 15 ml of buffer 1 (136 rnM NaCl. 2.7 rnM 
KCl. 0.42 rnM NaH2P04 • 12 rnM NaHC03• 2 rnM MgC12, 
2 mg/ml BSA (Sigma). 5.6 rnM glucose, 22 nM Na3citrate 50 
pH 6.5) and platelets were isolated at 2200 rpm at room 
temperature for 10 minutes. Platelets were washed once in 
15 ml buffer 1. then resuspended to 107 cells/ml in buffer 2 
(136 rnM NaCl, 2.7 rnM KCl. 0.42 rnM NaHzl'04 • 12 rnM 
NaHC03• 2 rnM MgCl. 1 mg/ml BSA (Sigma). 5.6 rnM 55 
glucose. 20 mM HEPES (Sigma) pH 7.4) and allowed to 
"rest" for a minimum of 10 minutes at room temperature 
before use. 
Inhibitors were added from stock solutions made fresh in 
DMSO. 100 µl platelets, suspended to 107 cells/ml in buffer 60 
2, were incubated with 1 µl of an inhibitor solution for 5 
minutes at room temperature prior to the addition of 2 mM 
Ca2+ and 1 uM A23187. After 10 minutes total exposure to 
inhibitor (5 minutes exposure to ionophore) at room 
temperature, platelets were reisolated at 14.000 rpm for 10 65 
sec in a Beckman microfuge. dissolved in SDS-PAGE 
sample buffer. and healed to 90° C. for 3 minutes. 
TABLE I 
Inhibition of Cysteine Proteases by Peptide a-Ketoamides. 
Ki(uM) 
Cal- Cal-
Peptide a-Ketoamide pain I pain II Cath B 
Z--Leu-Abu-CONH--Et 
Z--Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-IlBu 
Z--Leu-Abu-CONH-iBu 
Z--Leu-Abu-CONH-Bzl 
Z--Leu-Abu-CONH-{CH2)z-Ph 
Z--Leu-Abu-CONH-{CH2)s-Mpl 
Z--Leu-Abu-CONH-{CH,)7CH3 
Z--Leu-Abu-CONH-{CH2) 1,CH3 
Z-Leu-Abu-CONH-{CH2),0H 
Z-Leu-Abu-CONH-{CH2),0(CH2),0H 
Z-Leu-Phe-CONH--Et 
Z-Leu-Phe-CONH-nPr 
Z--Leu-Phe-CONH-IlBu 
Z--Leu-Phe-CONH-iBu 
Z--Leu-Phe-CONH-Bzl 
Z--Leu-Phe-CONH(CH2),Ph 
0.5 
0.2 
0.16 
7.0 
15.0 
0.23 
0.25 
0.14 
0.35 
0.022 
0.041 
0.019 
0.078 
0.32 
0.05 
0.028 
0.065 
0.046 
0.024 
2.4 
8 
13 
4 
2 
6 
3 
3 
4 
Table II shows the inhibition constants (K1) for PP elastase 
and chymotrpysin. Dipeptide a-ketoamides with Abu in the 
P 1 site are potent inhibitors of PP elastase. The structures 
with medium sized straight-chain alkyl groups such as n-Pr 
and n-Bu were better inhibitors than a small alkyl (Et) or 
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a branched alkyl (i-Bu). Dipeptide a-ketoamides with Phe 
in the P 1 site are moderate inhibitors of chymotrypsin. The 
inhibitor with R3=n-Bu and R4=H was the best in the 
series. In general the inhibitors were more potent at inhib-
iting cysteine protease than serine proteases. Extending the 5 
peptide chain to tripeptide or tetrapeptide ketoamides would 
improve the inhibitory potency toward serine proteases. 
TABLE III-continued 
Half-lives Plasma and in Liver and Activitv in the Platelet Assay. 
Peptide a-Ketoamide or Ester platelet 
2-NapCO-Leu-Leu-Abu-COOEt 
1112 
plasma 
25 
tll2 
liver 
TABLE II 
Inhibition of Serine Proteases by Peptide a-Ketoamides. 
Peptide a-Ketoamide 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH-nPr 
Z-Leu-Abu-CONH-nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Abu-CONH-(CH,)2-Ph 
z.-:.Leu-Abu-CONH-(CH2) 3-Mpl 
Z-Leu-Abu-CONH-(CH2).,CH3 
Z-Leu-Abu-CONH-(CH2) 17CH3 
Z-Leu-Abu-CONH-(CH2) 20H 
Z-Leu-Abu-CONH-(CH2) 20(CH2),0H 
Z-Leu-Phe-CONH-Et 
Z-Leu-Phe-CONH-nPr 
Z-Leu-Phe-CONH--nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH(CH,),Ph 
KiCuMl 
Chymo-
trypsin 
>150 
>300 
>300 
>300 
>300 
73 
18 
8 
24 
PP elastase 
65 
2 
5 
40 
>150 
>300 
>100 
Peptide a-ketoamide were substantially more stable in 
both plasma and liver than the corresponding peptide 
a-ketoesters (Table III). The peptide a-ketoamides were 
also much more effective in the platelet assay. Extending the 
R3 group to an alkyl group or an alkyl group substituted with 
a phenyl group increased the membrane permeability of the 
inhibitors as indicated by increased potency in the platelet 
assay. 
TABLE III 
Half-lives Plasma and in Liver and Activitv in the Platelet Assay. 
tll2 tll2 
Peptide a-Ketoamide or Ester platelet plasma liver 
Z-Leu-Abu-COOEt 42 2.8 
Z-Leu-Abu-COOn-Bu 28 
Z-Leu-Abu-COOBzl -I+ 
Z-Leu-Leu-Abu-COOEt 40 
2-NapS02-Leu-Leu-Abu-COOEt 100 >60 
0 
10 
15 
20 
25 
30 
Tos-Leu-Leu-Abu-COOEt 
Z-Leu-Abu-COOH 
Z-Leu-Abu-CONH-Et 
Z-Leu-Abu-CONH--fil'r 
Z-Leu-Abu-CONH--nBu 
Z-Leu-Abu-CONH-iBu 
Z-Leu-Abu-CONH-Bzl 
Z-Leu-Phe-COOEt 
Z-Leu-Phe-COOnBu 
Z-Leu-Phe-COOBz 
Z-Leu-Leu-Phe-COOEt 
Z-Leu-Phe-COOH 
Z-Leu-Phe-CONH-Et 
Z-Leu-Phe-CONH--fil'r 
Z-Leu-Phe-CONH-nBu 
Z-Leu-Phe-CONH-iBu 
Z-Leu-Phe-CONH-Bzl 
Z-Leu-Phe-CONH(CH2) 2Ph 
Z-Leu-Nle-COOEt 
Z-Leu-Nva-COOEt 
Z-Leu-Met-COOEt 
30 
8 
1.5 
70 
2.0 
28 
1.5 
42 
+++ 
-I+ 
-I+ 
6.5 
1.7 
24 
38 
22 
3.0 
20 
40 
+ 
30 
>60 
>60 
>60 
>60 
>60 
>60 
7.8 
7.7 
1.9 
>60 
>60 
>60 
>60 
>60 
>60 
3.7 
2.8 
8 
>60 
>60 
>60 
>60 
>60 
>60 
>60 
>60 
>60 
( +++ = excellent activity; -t+ = good activity, + = moderate activity; 
quantitative measurements not yet complete) 
Inhibition Mechanism. A crystal structure of one 
a-ketoester bound into the active site of porcine pancreatic 
elastase has been completed and a schematic drawing of the 
interactions observed is shown below. The active site Ser-
195 oxygen of the enzyme has added to the carbonyl group 
35 of the ketoester to form a tetrahedral intermediate which is 
stabilized by interactions with the oxyanion hole. This 
structure resembles the tetrahedral intermediate involved in 
peptide bond hydrolysis and proves that a-ketoesters are 
transition-state analogs. His-57 is hydrogen bonded to the 
45 
40 carbonyl group of the ester functional group, the peptide 
backbone on a section of PPE's backbone hydrogen bonds 
to the inhibitor to form a (3-sheet, and the benzyl ester is 
directed toward the S' subsites. The side chain of the P 1 
amino acid residue is located in the S1 pocket of the enzyme. 
Interactions with ketoamides would be similar except for 
that there would be the possibility of forming an additional 
hydrogen bond with the NH group of the ketoamide func-
tional group if R3 or R4 was H. If R3 and/or R4 are longer 
substituents, then they would make favorable interactions 
with the S' subsites of the enzyme. 
~j~(;~ 
I o- o 
S' subsites 
' 
•H 
iI b oxyanion \ 
N~ 
~N...._H 
His-57 I hole 
/Ny"' N~ 
Val-216 0 H Ser-214 
Phe-214 
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The active site of cysteine proteases share several features strategy will also work when other classes of peptide inhibi-
tors are used in place of the peptide substrate to gain 
information on the appropriate sequence to place in the 
ketoester. ketoacid. or ketoamide inhibitor. Thus. we are able 
to predict the structure of new inhibitors for other serine and 
cysteine proteases based on knowledge of their substrate 
specificities. Once a good inhibitor structure for a particular 
enzyme is found, it is then possible to change other char-
acteristics such as solubility or hydrophobicity by adding 
substituents to the M 1 or R3 and R4 groups. 
in common with serine proteases including an active site 
histidine residue. In place of the Ser-195. cysteine proteases 
have an active site cysteine residue which would add to the 
ketonic carbonyl group of the peptide keto acids. keto esters. 5 
or ketoamides to form an adduct very similar to the structure 
depicted above except with a cysteine residue replacing the 
serine-195 residue. Additional interactions would occur 
between the extended substrate binding site of the cysteine 
protease and the inhibitor which would increase the binding 
10 
affinity and specificity of the inhibitors. 
Inhibitor Design and Selection. The peptide and amino 
acid a-ketoamide derivatives. as shown in the above crystal 
structure. bind to the enzymes using many of the interactions 
that are found in complexes of a particular individual 
enzyme with its substrates. In order to design an inhibitor for 15 
a particular serine or cysteine protease. it is necessary to: 1) 
find the amino acid sequences of good peptide substrates for 
that enzyme. and 2) place those or similar amino acid 
sequences into a a-ketoamide structure. Additional interac-
tions with the enzyme can be obtained by tailoring the R 20 
group of the inhibitor to imitate the amino acid residues 
which are preferred by an individual protease at the Si' and 
S2 ' subsites. For example. ketoesters with R3 and/or 
R4=branched alkyl groups would interact effectively with 
serine and cysteine proteases which prefer Leu. Ile. and Val 25 
residues at P1' and/or P2'. while amides with R=alkyl sub-
stituted with phenyl would interact effectively with serine 
and cysteine proteases which prefer Phe. Tyr. Trp residues at 
P1' and/or P2 '. Likewise. the M1 group can be tailored to 
interact with the S subsites of the enzyme. This design 
Elastase is an enzyme which hydrolyzes most effectively 
tetra- and tripeptides having P 1 residues with small alkyl 
side chains such as Ala and Val. MeO-Suc-Ala-Ala-
Ala-Val-NA and Z-Ala-Ala-Ala-Ala-NA are 
good substrates (NA=4-nilroanilide). Thus the correspond-
ing a-ketoamide Z-Ala-Ala-Ala-DL-Ala--CO-
NR3R4 and Me0-Suc-Ala-Ala-Pro-DL-Abu-
CO-NR3R4 will be excellent elastase inhibitors. Suc-
Phe-Leu-Phe-NA is an excellent substrate for 
chyrnotrypsin. cathepsin G. and mast cell chymases. Thus. 
the corresponding a-ketoamide will be an excellent inhibitor 
for these chymotrypsin-like enzymes. In the case of the 
cysteine protease calpain. a good inhibitor sequence is 
Ac-Leu-Leu-Nle-H. We have found that ketoesters 
related in structure such as Z-Leu-Abu--CO-NR3R4 
and Z-Leu--Phe--CO-NR3R4 are potent inhibitors for 
cal pain. 
The following structures are predicted to be potent inhibi-
tors for the listed enzymes. The inhibitor sequences were 
obtained from peptide substrate and/or inhibitor sequences 
in the protease literature. 
Z---Gly-Leu-Phe---CO-NR3R4 for cathepsin G and RMCP II 
Me0-Suc-Ala-Ala--Pro--Met---CO-NR3R4 for cathepsin G 
Boc-Ala-Ala-Asp-CO-NR3R4 for human lymphocyte grauzyme B 
Suc-Pro--Leu-Phe---CO-NR,R4 and Boc-Ala-Ala-Phe---CO-NR3R4 
for RMCP I (RMCP =rat mast cell protease) 
Bcc-Gly-Leu-Phe---CO-NR3 R4, Suc-Phe-Leu-Phe---CO-NR3R4 
for human aud dog skin chymase 
Bcc-Ala-Ala-Glu---CO-NR3R4 for S. aureus V-8 protease 
Z---Gly-Gly-Pro-CO-NR3R4 for human prolyl endopeptidase 
Ala-Pro-CO-NR3R4 for DPP IV 
Suc-Ala-Ala--Pro--Val---CO-NR3R4 for PPE 
Suc---Lys(Cbz)-Val-Pro-Val---CO-NR3R4, adamantyl-S02---Lys(COCH2CH2C02H)-Ala-Val-
CO-NR3R4, adamautyl---CH2CH20CO-Glu(O---t-Bu)--Pro--Val---CO-NR3R4 , and adamautyl-
S02_,_y-<eo--a;H4C02H)-Ala-Val---CO-NR3R4 for human leukocyte(neutrophil) elastase 
Suc-Ala-Ala-Pro--Leu---CO-NR3R4 for elastolytic proteinase from "Schistosoma 
mansoni'' 
Glu-Phe---Lys---CO-NR3R4 and Dns-Ala-Phe-Lys---CO-NR3R4 
for plasmin 
D-Val-Gly-Arg---CO-NR3R4 and Dns-Glu-Gly-Arg---CO-NR3R4 
for factor Xa 
Z--Phe-Arg---CO-NR3R4 and Z-Trp-Arg---CO-NR3R4 
Z---Lys---Arg---CO-NR3R4 
Z---Gly-Arg---CO-NR3R4 
Z-Ile-Ala-Gly-Arg---CO-NR3R4 
for porcine pancreatic and human plasma 
kallikreins 
for human skin tryptase 
for human luug tryptase 
for factors IXa, Xa, Xia, XIIa aud 
bovine plasma kallikrein 
Glu-Gly-Arg---CO-NR3R4 for urokinase 
Dns-Phe--Pro--Arg---CO-NR3R4 for plasminogen activator 
Dns---Ile-Pro-Arg---CO-NR3R4 for activated protein C 
Z-Trp--Arg---CO-NR3R4 for bovine factor IXa 
Z---Gly-Arg---CO-NR3R4 for bovine factor Xa and Xia 
Z-Phe-Arg---CO-NR3R4 for bovine factor Xlla 
Dns---Glu-Gly-Arg---CO-NR3R4 for human factor Xa 
D-Phe-Pro-Arg---CO-NR3R4, D-MePhe-Pro-Arg---CO-NR3R4 , and 
Bcc-D-Phe-Pro-Arg---CO-NR3R4 for human thrombin 
Z--Phe-Gly-Arg---CO-NR3R4 for trypsin 
Cl---CJI4CH,OCO-Phe-Gly---CO-NR3R4 for papain 
C6H,;CH2NHCO-Gly-Phe-Gly---CO-NR3R4 
for cathepsin B 
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R3 and R4 are selected independently from the group 
consisting ofH, C1_20 alkyl, C3_20 cyclized alkyl. C1_20 alkyl 
with a phenyl group attached to the C1_20 alkyl. C3 _20 
cyclized alkyl with an attached phenyl group, C1_20 alkyl 
with an attached phenyl group substituted with K. C1_20 
alkyl with an attached phenyl group disubstituted with K. 
C1_20 alkyl with an attached phenyl group trisubstituted with 
K. c3-20 cyclized alkyl with an attached phenyl group 
substituted with K, C1_10 alkyl with a mo.rpholine [-N 
(CH2CH~O] ring attached through nitrogen to the alkyl. 
C1_10 alkyl with a piperidine ring attached through nitrogen 
to the alkyl. cl-10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl. C1_20 alkyl with an OH group 
attached to the alkyl. -CH2CH20CH2CH20H, C1_10 with 
an attached 4-pyridyl group, C1_10 with an attached 
3-pyridyl group, C1_10 with an attached 2-pyridyl group, 
C1_10 with an attached cyclohexyl group, -NH-
CH2CH2--( 4-hydroxyphenyl), and -NH-CH2CH2--(3-
indolyl). 
In Vitro Uses. To use the above inhibitors in vitro, they are 
dissolved in an organic solvent such as dimethylsulfoxide or 
ethanol, and are added to an aqueous solution containing 
seine and/or cysteine proteases. The final concentration of 
the organic solvent should be less than 25%. The inhibitors 
may also be added as solids or in suspension. The serine and 
cysteine protease inhibitors of this invention would be useful 
in a variety of experimental procedures where proteolysis is 
a significant problem. Inclusion of these inhibitors in a 
radioimmunoassay experiments would result in higher sen-
sitivity. The use of these inhibitors in plasma fractionation 
procedures would result in higher yields of valuable plasma 
proteins and would make purification of the proteins easier. 
The inhibitors disclosed here could be used in cloning 
experiments utilizing bacterial cultures, yeast and human 
cells to yield a purified cloned product in higher yield. 
20 
lung elastin and alveoli. The destructive changes of lung 
parentchyma associated with pulmonary emphysema are 
caused by uncontrolled proteolysis in lung tissues [Janoff, 
Chest 83, 54-58 (1983); incorporated herein by reference]. 
5 A number of proteases have been shown to induce emphy-
sema in animals [Marco et al., Am. Rev. Respir. Dis. 104, 
595-598 (1971); Kaplan, J. Lab. Clin. Med. 82, 349-356 
(1973); incorporated herein by reference], particularly 
human leukocyte elastase [Janoff, ibid 115, 461-478 (1977); 
10 incorporated herein by reference]. Leukocyte elastase and 
other mediators of inflammation also appear to play a role in 
diseases such as mucocutaneous lymph node syndrome 
[Reiger et al .. Eur. J. Pediatr. 140, 92-97 (1983); incorpo-
rated herein by reference] and adult respiratory distress 
15 syndrome [Stockley, Clinical Science 64, 119-126 (1983); 
Lee et al., N. Eng. J. Med. 304, 192-196 (!981); Rinaldo, 
ibid301, 900-909 (1982); incorporated herein by reference]. 
It is known that in vitro activity of elastase inhibitors 
correlates with in vivo activity in animal models of emphy-
20 sema and inflammation [Otterness et al., editors, Advances 
in Inflammation Research, Vol. 11, Raven Press 1986; 
incorporated herein by reference]. Prophylactic administra-
tion of an inhibitor of elastase significantly diminishes the 
extent of elastase-induced emphysema [Kleinerman et al., 
25 Am. Rev. Resir. Dis. 121,381-387 (1980);Luceyet. al., Eur. 
Respir. J. 2, 421-427 (1989); incorporated herein by 
reference]. Thus the novel inhibitors described here should 
be useful for the treatment of emphysema and inflammation. 
Elastase inhibitors have been used orally, by injection, or by 
30 instillation in the lungs in animal studies (Powers, Am. Rev. 
Respir. Dis., 127, s54-s58 (1983); Powers and Bengali, Am. 
Rev. Respir. Dis. 134, 1097-1100 (1986); these two articles 
are incorporated herein by reference). The inhibitors 
described above can be used by any of these routes. 
The novel compounds of this invention are effective in the 35 
prevention of unnecessary proteolysis caused by 
chymotrypsin-like and elastase-like enzymes in the process 
Drug Delivery. For therapeutic use, the peptide 
a-ketoarnides may be administered orally, topically or 
parenterally. The term parenteral as used includes subcuta-
neous injection, intravenous, intramuscular, intrasternal 
injection or infusion techniques. The dosage depends pri-
of purification, transport and storage of peptides and pro-
teins as shown in Table II by effective inhibition of chy-
motrypsin and elastase and other cysteine proteases. 
In Vivo Uses. Effective inhibitors of the proteolytic func-
tion of human leukocyte elastase and chymotrypsin-like 
enzymes (Table II) would have anti-inflammatory activity 
and can be used to treat and control emphysema, adult 
respiratory distress syndrome and rheumatoid arthritis. 
Effective inhibitors of the proteolytic function of chymot-
rypsin and pancreatic elastase (Table ll) are effective for 
therapeutic use in the treatment of pancreatitis. 
Peptide a-ketoarnide can be used to control protein 
turnover, muscular dystrophy, myocardial tissue damage, 
tumor metastasis, and bone resorption as shown in Table I by 
effective inhibition of lysosomal cathepsin B in buffer. 
Peptide a-ketoarnides can also be used as neuroprotectants 
or for the treatment of ischemia, stroke or Alzheimer's 
disease as shown in Table I by effective inhibition of calpain 
I and calpain II. 
Considerable evidence has shown that leukocyte elastase 
and/or related enzymes play a role in tumor cell metastasis 
[Salo et al., Int. J. Cancer 30, pp 669-673 (1973); Kao et al., 
Biochem. Biophys. Res. Comm. 105, pp 383-389 (1982); 
Powers, J. C. in Modification of Proteins, R. E. Feeney and 
J. R. Whitaker, eds., Adv. Chem. Ser 198,Amer. Chem. Soc., 
Wash., D.C. pp 347-367 (1982); all incorporated herein by 
reference], therefore it is suggested that compounds of this 
invention may have anti-tumor activity. 
Pulmonary emphysema is a disease characterized by 
progressive loss of lung elasticity due to the destruction of 
40 marily on the specific formulation and on the object of the 
therapy or prophylaxis. The amount of the individual doses 
as well as the administration is best determined by individu-
ally assessing the particular case. 
The pharmaceutical compositions containing the active 
45 ingredient may be in a form suitable for oral use, for 
example as tablets, troches, lozenges, aqueous or oily 
suspensions, dispersible powders or granules, emulsions, 
hard or soft capsules or syrups or elixirs. Dosage levels of 
the order to 0.2 mg to 140 mg per kilogram of body weight 
50 per day are useful in the treatment of above-indicated 
conditions (10 mg to 7 gms per patient per day). The amount 
of active ingredient that may be combined with carrier 
materials to produce a single dosage form will vary depend-
ing upon the host treated and the particular mode of admin-
55 istration. 
For injection, the therapeutic amount of the peptide 
a-ketoarnides or their pharmaceutically acceptable salts will 
normally be in the dosage range from 0.2 to 140 mg/kg of 
body weight. Administration is made by intravenous, intra-
60 muscular or subscutaneous injection. Accordingly, pharma-
ceutical compositions for parenteral administration will con-
tain in a single dosage form about 10 mg to 7 grns of the 
compounds per dose. In addition to the active ingredient, 
these pharmaceutical compositions will usually contain a 
65 buffer, e.g. a phosphate buffer which keeps the pH in the 
range from 3.5 to 7 and also sodium chloride, mannitol or 
sorbitol for adjusting the isotonic pressure. 
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A composition for topical application can be formulated 
as an aqueous solution. lotion. jelly or an oily solution or 
suspension. A composition in the form of an aqueous solu-
tion is obtained by dissolving the compounds of this inven-
tion in aqueous buffer solution of pH 4 to 6.5 and if desired. 
adding a polymeric binder. An oily formulation for topical 
application is obtained by suspending the compounds of this 
invention in an oil. optionally with the addition of a swelling 
agent such as aluminium stearate and/or a surfactant. 
SYNTHETIC MEI'HODS 
The a-ketoamide inhibitors are prepared from the corre-
sponding a-ketoaamide. The ketoester inhibitors are pre-
pared by a two step Dakin-West from the corresponding 
peptide acid (Charles et al .• J. Chem. Soc. Perkin 1. 
1139-1146.1980). This procedure can be utilized with either 
amino acid derivatives. dipeptide derivatives. tripeptide 
derivatives. or tetrapeptide derivatives as shown in the 
following scheme. 
M 1-AA-OH---7Enol Ester---7M1-AA---CO-O-R 
M 1-AA-AA-OH---7EI10l Ester---7M1-AA-AA---C0-0-R 
M 1-AA-AA-AA-OH---7Enol Ester---7M1-AA-AA-AA-
CO-O-R 
M 1-AA-AA-AA-AA-OH---7Enol Ester---7M1-AA-AA-
AA-AA---CO-O-R 
The precursor peptide can be prepared using standard pep-
tide chemistry which is well described in publications such 
22 
Me0-CO-CH2CH2-CO-Cl would give the X---CO-
group where X is a C2 alkyl substituted with a C1 alkyl-
OCO-group. Reaction with a substituted alkyl or aryl thio-
acid chloride would introduce a thioacyl group (M=X-
5 CS-). Reaction with an a substituted alkyl or aryl sulfonyl 
chloride would introduce an X-S02-group. For example 
reaction with clansyl chloride would give the X-S02-
derivative where X was a naphthyl group mono substituted 
10 with a dimethylamino group. Reaction with a substituted 
alkyl or aryl chloroformate would introduce a X-0---CO-
group. Reaction with a substituted alkyl or aryl chlorothio-
formate would introduce a X---0-CS-. There are many 
alternate reaction schemes which could be used to introduce 
15 all of the above M1 groups to give either M1-AA-OH or 
M1-AA-OR1. 
The M1-AA-OH derivatives could then be used 
directly in the Dakin-West reaction or could be converted 
20 into the dipeptides. tripeptides. and tetrapeptides 
M 1-AA-AA-OH. M 1-AA-AA-AA-OH. or 
M1-AA-AA-AA-AA-OH which could be used in 
the Dakin-West reaction. The substituted peptides 
M 1-AA-AA-OH. M 1-AA-AA-AA-OH. or 
25 M 1-AA-AA-AA-AA-OH could also be prepared 
directly from H-AA-AA-OH. H-AA-AA-AA-
OH. or H-AA-AA-AA-AA-OH using the reactions 
described above for introduction of the M1 group. 
30 Alternately. the M1 group could be introduced by reaction 
with carboxyl blocked peptides to give M 1-AA-AA-
OR'. M 1-AA-AA-AA-OR'. or M1-AA-AA-
AA-AA-OR'. followed by the removal of the blocking as The Peptides, Analysis, Synthesis, Biology, Vol. 1-9. 
published in 1979-1987 by Academic Press and Houben-
Weyl Methoden der Organischen Chemie. Vol. 15. Parts 1 35 
and 2. Synthese von Peptiden. published by Georg Thieme 
Verlag. Stuttgart in 1974 (both references incorporated 
herein by reference). 
group R'. 
The R group in the ketoester structures is introduced 
during the Dakin-West reaction by reaction with an oxalyl 
chloride Cl-CO---C0-0-R. For example. reaction of 
M 1-AA-AA-OH with ethyl oxalyl chloride C1---CO-The M1 group can be introduced using a number of 
different reaction schemes. First it could be introduced 40 
directly on an amino acid as shown in the following scheme 
(top). or the M1 group could be introduced by reaction with 
an amino acid ester. followed by removal of the ester group 
to give the same product (bottom). 
CO-O-Et gives the keto ester M1-AA-AA---CO-
O-Et. Reaction of M1 -AA-AA-AA-AA-OH with 
Cl-CO-C0-0-Bzl would give the ketoester 
M 1-AA-AA-AA-AA---C0-0-Bzl. Clearly a wide 
variety of R groups can be introduced into the ketoester 
H-AA-OH---7M1-AA-OH 
H-AA-0 R'---7M1-AA-0 R'---7M1-AA-OH 
45 structure by reaction with various alkyl or arylalkyl oxalyl 
chlorides (Cl---CO---C0-0-R). The oxalyl chlorides are 
easily prepared by reaction of an alkyl or arylalkyl alcohol 
with oxalyl chloride Cl-CO-CO-Cl. For example. 
The techniques for introduction of the M1 group is well 50 
documented in the The Peptides. Houben-Weyel. and many 
other textbooks on organic synthesis. For example reaction 
with cyanate or p-nitrophenyl cyanate would introduce a 
carbamyl group (M 1=NH2 CO-). Reaction with 
Me2NCOC1 would introduce the Me2NCO-group. Reaction 55 
with p-nitrophenyl thiocarbamate would introduce a thio 
carbamyl group (M 1-NH2CS-). Reaction with 
NH2S02Cl would introduce the NH2S02-group. Reaction 
with MezNS02Cl would introduce the Me2NS02-group. 
Reaction with a substituted alkyl or aryl isocyanate would 60 
introduce the X-NH-CO-group where X is a substituted 
alkyl or aryl group. Reaction with a substituted alkyl or aryl 
isothiocyanate would introduce the X-NH-CS-group 
where X is a substituted alkyl or aryl group. Reaction with 
X-S02-Cl would introduce the X-SOrgroup. Reaction 65 
with a substituted alkyl or aryl acid chloride would introduce 
an acyl group (M=X-CO-). For example. reaction with 
Bzl-0---CO-CO---Cl and n-Bu-0---CO-CO-Cl 
are prepared by reaction of respectively benzyl alcohol and 
butanol with oxalyl chloride in yields of 50% and 80% 
[Warren. C. B .. and Malee. E. J .• J. Chromatography 64, 
219-222 (1972); incorporated herein by reference]. 
Ketoamides M1-AA-CO-NR3R4• M-AA-AA-
C O-NR3R4. M-AA-AA-AA-CO-NR3R4, 
M-AA-AA-AA-AA---CO-NR3R4 were prepared 
indirectly from the ketoesters. The ketone carbonyl group 
was first protected as shown in the following scheme and 
then the ketoarnide was prepared by reaction with an amine 
H-NR3R4. The illustrated procedure should also work with 
other protecting groups. In addition. the corresponding 
ketoacid could be used as a precursor. Blocking the ketone 
carbonyl group of the ketoacid and then coupling with an 
amine H-NR3R4 using standard peptide coupling reagents 
would yield an intermediate which could then be deblocked 
to form the ketoamide. 
23 
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and ethylmine was bubbled through the solution until 2.43 
g (54 mmole) had been added. The reaction mixture was 
allowed to warm to room temperature slowly, and stirred 
overnight. The mixture was filtered. a white precipitate was 
5 removed. leaving a yellow semisolid. Chromatography on a 
silica gel column with CHC13'CH30H (30:1 v/v) afford 0.63 
g (y=75%) of Z-Leu-Phe---CONH-Et. The product was 
a pale yellow solid. Single spot on TLC, R_t=0.60 (CHC13' 
CH30H 20:1); mp 145°-147° C. Anal. calcd. for 
10 C26H33N30 5: 467.56; C, 66.79; H, 7.11; N. 8.99; found: C, 
66.59; H, 7.09; N, 8.95. NMR (CDC13) ok. MS (FAB) 
m/e=468 (M+l). 
EXAMPLE2 
15 Z-Leu-Phe---CONH-nPr 
The following detailed examples are given to illustrate the 20 
invention and are not intended to limit it in any mariner. 
This compound was synthesized from the protected 
a-ketoester and propylamine in 92% yield by the procedure 
described in Example 1. Single spot on TLC, R_t=0.50 
(CHC13/CH30H 50:1); mp 152°-153 ° C. Anal. calcd. for 
C27H35N30 5: 481.57; C, 67.33; H, 7.33; N, 8.72. Found: C, 
67.21; H. 7.38; N, 8.64. NMR (CDC13) ok. MS (FAB) 
EXAMPLE 1 m/e=482 (M+l). 
Z-Leu-Phe---CONH-Et EXAMPLE3 
To a stirred solution of Z-Leu-Phe-OH (20 g, 48.5 25 Z-Leu-Phe---CONH-nBu 
mmole), 4-dimethylaminopyridine (0.587 g, 4.8 mmole), 
and pyridine (15.7 ml, 194 mmole) in anhydrous THF (100 
ml) was added ethyl oxalyl chloride (11.4 ml, 101.8 mmole) 
This compound was synthesized from the protected 
a-ketoester and butylarnine in 67% yield by the procedure 
described in Example 1. Single spot on TLC, R_t=0.50. 
(CHC13'CH30H 50:1); mp 152°-153 ° C. Anal. calcd. for 
C28H37N30 5: 495.59; C. 67.85; H, 7.52; N, 8.48. Found: C, 
67.70; H, 7.57; N, 8.43. NMR (CDC13) ok. MS (FAB) 
m/e=496 (M+l). 
EXAMPLE4 
at a rate sufficient to initiate refluxing. The mixture was 
gently refluxed for 4 hours, cooled to room temperature, and 30 
water (80 ml) was added. The reaction mixture was stirred 
vigorously for 30 min, and extracted with ethyl acetate 
(3x100 ml). The combined organic layers were washed with 
water (2x100 ml), saturated sodium chloride (2x100 ml), 
decolorized with decolorizing carbon, dried over magne- 35 
sium sulfate, and concentrated, leaving a dark orange oil. Z-Leu-Phe---CONH-iBu 
Chromatography on a silica gel column with CHCl3/CH30H This compound was synthesized from the protected 
(50:1 v/v) afforded 14.63 g (y=53%;) o~ Z-Leu-Phe- a-ketoester and isobutylarnine in 53% yield by the proce-
enolester. The product was a yellow oil. Smgle spot on TLC, dure described in Example 1. Single spot on TLC, R_t=0.54 
R_t=0.77 (~HCL3'CH30H 50:1 ): NMR (CDCl3) ok. (CHCI /CH OH 50:1)· mp 152° C. Anal. calcd. for 
To a stirred pale yellow solution of the Z-Leu-Phe- 40 3 3 ' 
enolester (14.63 g, 25.73 mmole) in anhydrous ethanol (50 C2sH37N30s: 495.59; C, 67.85; H, 7.52; N, 8.48. Found: C, 
ml) was added a solution of sodium ethoxide (0.177 g, 2.6 67·7!; H. 7.56; N. 8.40. NMR (CDCl3) ok. MS (FAB) 
mmole) in ethanol (5 ml). The orange solution was stirred me/=496 (M+l). 
for 3 hours at room temperature, then the ethanol was 
evaporated and the residue was treated with ethyl ether (300 45 EXAMPLES 
ml). The ether layer was washed with water (2xl00 ml). Z-Leu-Phe-CONH---Bzl 
saturated sodium chloride (2x100 ml), dried over magne- This compound was synthesized from the protected 
sium sulfate, and concentrated, leaving a orange oil. Chro- a-ketoester and benzylarnine in 40% yield by the procedure 
matography on a silica gel column with CHC13/CH30H described in Example 1. After reacting overnight. ethyl (50:1 v/v) afforded 7.76 g (y=64%) of the a-ketoester 50 acetate (60 ml) was added. The mixture was filtered to 
Z-Leu-Phe---COOEt. The product was a yellow oil. remove a white precipitate. The solution was washed with 
Single spot on TLC, R_t=0.44 (CHC13'CH30H 50:1). NMR cooled lN HCl (3x25 ml), water (lx20 ml), saturated (CDC13) ok. MS (FAB, calcd. for C26H32N20 6 : 468.6), sodium chloride (2x20 ml), and dried over magnesium 
m/e=469 (M+l). sulfate. The solution was evaporated leaving a yellow solid. 
The a-carbonyl group of Z-Leu-Phe---COOEt was 55 Chromatography on a silica gel column with CHC13'CH30H 
protected by the following procedure. To a solution of 30:1 v/v) afforded a yellow solid. Single spot on TLC, 
Z-Leu-Phe---COOEt (1 g. 2.13 mmole) in 5 ml of R.f=0.45 (CHC1/CH30H 30:1); mp 160°-162° C. Anal. 
CH2Cl2 was added 1.2-ethanedithiol (0.214 ml, 2.55 calcd. for C31H35N30 5: 529.61; C, 70.30; H. 6.66; N, 7.93. 
mmole), followed by 0.5 ml of boron trifluoride etherate. Found: C, 70.18; H, 6.67; N, 7.99. NMR (CDC13) ok. MS 
The solution was stirred overnight at room temperature. 60 (FAB) m/e=530 (M+l). 
Water (20 ml) and ethyl ether (20 ml) were added. The 
organic layer was separated, washed with water (2x10 ml), 
saturated sodium chloride (2x 10 ml), dried over magnesium 
sulfate, and evaporated to afford 0.98 g (y=84%) yellow 
semisolid. 
The protected a-ketoester (0.98 g, 1.8 mmole) was dis-
solved in ethanol (5 ml), cooled to 0°-5° C. in an ice bath, 
EXAMPLE6 
Z-Leu-Phe---CONH-{CH2hPh 
This compound was synthesized from the protected 
65 a-ketoester and phenethylamine in 50% yield by the pro-
cedure described in Example 5. Single spot on TLC, R_t=0.50 
(CHC13'CH30H 30:1); mp 151°-153° C. Anal. calcd. for 
5,650,508 
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C32H37N30 5: 543.66; C. 70.70; H. 6.86; N. 7.73. Found: C. 
70.54; H. 6.88; N. 7.74. NMR (CDC13) ok. MS (FAB) 
rn/e=544 (M+l). 
EXAMPLE 7 
~Leu-Abu-CONH-Et 
This compound was synthesized from protected 
a-ketoester derived from ~Leu-Abu-COzEt and ethy-
larnine in 64% yield by the procedure described in Example 
1. Single spot on 1LC. R,=0.36 (CHC1JCH30H 50;1); mp 
130°-132° C. Anal. calcd. for C21H31N30 5: 405.45; C. 
62.20; H. 7.71; N.10.36. Found: C. 61.92; H. 7.62; N.10.31. 
NMR (CDC13) ok. MS (FAB) m/e=406 (M+l). 
EXAMPLE 8 
~Leu-Abu-CONH-nPr 
26 
EXAMPLE13 
~Leu-Abu-CONH-(CH2)3-N(CH2CHz)20 
This compound was synthesized from protected 
5 
a-ketoester and 4(3-arninopropyl)morpholine in 33% yield 
by the procedure described in Example 1. After reacting 
overnight. ethyl acetate (80 ml) was added. The mixture was 
filtered to remove a white precipitate. The solution was 
washed with water (3x20 ml). saturated sodium chloride 
(2x20 ml). and dried over magnesium sulfate. The solution 
10 
was evaporated leaving a yellow oil. Chromatography on a 
silica gel column with CHC13'CH30H (10:1 v/v) afforded a 
yellow semisolid. which was recrystallized from ethyl 
acetate/hexane to obtain a pale yellow solid. Single spot on 
15 
TLC. R,=0.42 (CHC1JCH30H 10:1); mp 125°-126° C. 
Anal. calcd. for C26H4oN40 6: 504.63; C. 61.88; H. 7.99; N. 
11.10. Found: C. 61.69; H. 7.95; N. 11.07. NMR (CDC13 ) 
ok. MS (FAB) m/e=505 (M+l). 
This compound was synthesized from the corresponding 
protected a-ketoester and propylarnine in 47% yield by the 
procedure described in Example 1. Single spot on 1LC. 20 
R,=0.28 (CHC1JCH30H 50:1); mp 134°-135° C. Anal. 
calcd. for C22H33N30 5: 419.50; C. 62.98; H. 7.93; N. 10.02. 
Found: C. 62.84; H. 7.97; N. 9.94. NMR (CDC13) ok MS 
EXAMPLE 14 
~Leu-Abu-CONH-(CH2),CH3 
This compound was synthesized from the corresponding 
protected a-ketoester and octylarnine in 67% yield by the 
procedure described in Example 5. It was while solid. Single (FAB) m/e=420 (M+l). 
EXAMPLE9 
~Leu-Abu-CONH-nBu 
25 spot on TLC. R,=0.55 (CHC13'CH30H 30:1); mp 134°-135° 
C. Anal. calcd. for C27H43N30 5: 489.66; C. 66.23; H. 8.85; 
N. 8.58. Found: C. 66.19; H. 8.81; N. 8.61. NMR (CDC13) 
ok. MS (FAB) m/e=490 (M+l). 
EXAMPLE 15 
~Leu-Abu-CONH-(CH2)20H 
This compound was synthesized from the corresponding 
protected a-ketoester and butyl amine in 42% yield by the 30 
procedure described in Example 1. Single spot on TLC. 
R,=0.54 (CHC1JCH30H 50:1 ); mp 135°-136° C. Anal. 
calcd. for C23H35N30 5: 433.53; C, 63.71; H. 8.13; N. 9.69. 
Found: C. 63.48; H. 8.07; N. 9.67. NMR (CDC13) ok MS 
(FAB) m/e=434 (M+l). 
This compound was synthesized from the corresponding 
protected a-ketoester and ethanolarnine in 29% yield by the 
procedure described in Example 13. The product was a 
35 white sticky solid. Single spot on 1LC. R,=0.42 (CHClJ 
CH30H 10:1); mp 151°-153° C. Anal: calcd. for 
EXAMPLE 10 C21H31N30 6 : 421.49; C. 59.84; H. 7.41; N. 9.97. Found: C. 
"L -Ab -CONH-iB 59.11; H. 7.44; N. 9.81. NMR (CDC13) ok. MS (FAB) ~ eu u u rn/e=422 (M+l) 
This compound was synthesized from the corresponding 40 · 
protected a-ketoester and isobutylarnine in 65% yield by the EXAMPLE 16 
procedure described in Example 1. Single spot on 1LC. 
R,=0.25 (CHC!iCH30H 50:1); mp 133°-135° C. Anal. 
calcd. for C23H35N30 5: 433.52; C. 63.72; H. 8.14; N. 9.69. 
Found: C. 63.46; H. 8.10; N. 9.60. NMR (CDC13) ok MS 45 (FAB) m/e=434 (M+l). 
~Leu-Abu-CONH-(CH2)20(CH2h0H 
This compound was synthesized from the corresponding 
protected a-ketoester and 2-(2-arninoethoxy)ethanol in 34% 
yield by the procedure described in Example 13. The prod-
uct was white sticky solid. Single spot on TLC. R,=0.42 
(CHCliCH30H 10:1); mp 103°-105° C. Anal.: calcd. for 
C23H35N30 7: 465.55; C. 59.34; H. 7.58; N. 9.03. Found: C. 
59.23; H, 7.58; N. 9.01. NMR (CDC13) ok. MS (FAB) 
EXAMPLEll 
~Leu-Abu-CONH-Bzl 
This compound was synthesized from the corresponding 
protected a-ketoester and benzylarnine in 29% yield by the 
procedure described in Example 5. Single spot on 1LC. 
50 
rn/e=466 (M+l). 
EXAMPLE 17 
R,=0.56 (CHC1JCH30H 30:1); mp 140°-141° C. Anal. ~Leu-Abu-CONH-(CH2) 17CH3 
calcd. for C26H33N305: 467.54; C. 66.79; H. 7.11; N. 8.99. This compound was synthesized from the corresponding 
Found: C. 66.65; H. 7.07; N. 8.93. NMR (CDCl3) ok MS 55 protected a-ketoester and octadecylarnine in 12% yield by 
(FAB) mle=468 (M+l). the procedure described in Example 5. The product was a 
EXAMPLE 12 
~Leu-Abu-CONH-(CH2)2Ph 
This compound was synthesized from the corresponding 
protected a-ketoester and phenethylarnine in 51 % yield by 
the procedure described in Example 5. Single spot on 1LC. 
R,=0.44 (CHC1JCH30H 30:1); mp 156°-157° C. Anal. 
calcd. for C27H35N30 5: 481.59; C. 67.34; H. 7.33; N. 8.72. 
Found: C. 67.38; H. 7.33; N. 8.78. NMR (CDC13) ok. MS 
(FAB) m/e=482 (M+l). 
pale yellow solid. Single spot on 1LC. R,=0.54 (CHClJ 
CH30H 30:1); mp 134°-136° C. Anal: calcd. for 
60 C37H63N30 5: 629.92; C. 70.55; H. 10.08; N. 6.67. Found: C. 
70.71; H, 10.14; N. 6.75. NMR (CDC13) ok. MS (FAB) 
m/e=630.2 (M+l). 
EXAMPLE 18 
65 ~Leu-Abu-CONH-CH2-C6H3(0CH3)z 
This compound was synthesized from the corresponding 
protected a-ketoester and 3.5-dirnethoxybenzylarnine in 
5,650,508 
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45% yield by the procedure described in Example 5. The 
product was yellow sticky solid. Single spot on 1LC. 
R_F0.44 (CHC1:/CH30H 30:1); mp 153°-155° C. Anal.: 
calcd. for C28H37N30 7: 527.62; C. 63.74; H. 7.07; N. 7.96. 
Found: C. 63.66; H. 7.09; N, 7.92. NMR (CDC13) ok. MS 5 
(FAB) m/e=528.8 (M+l). 
EXAMPLE 19 
Z-Leu-Abu-CONH-CH2-C4H4N 
This compound was synthesized from the corresponding 10 
protected a-ketoester and 4-(aminomethyl)pyridine in 45% 
yield by the procedure described in Example 13. The prod-
uct was greenish yellow solid. Single spot on 1LC, R_t=0.55 
(CHC13/CH30H 10:1); mp 124°-126° C. Anal: calcd. for 
C25H32N40 5: 468.55; C. 64.08; H. 6.88; N. 11.96. Found: C. 15 
63.88; H. 6.87; N. 11.96. NMR (CDC13) ok. MS (FAB) m/e 
=469 (M+l). 
It is obvious that those skilled in the art may make 
modifications to the invention without departing from the 
spirit of the invention or the scope of the subjoined claims 20 
and their equivalents. 
What is claimed is: 
1. A peptide ketoamide compound of the formula: 
M 1-AA,-AARES-CO-NH-R4 
or a pharmaceutically acceptable salt. wherein 
AARES represents -NH-CHR2-CO-. 
25 
M1 represents H. NH2-CO-. NH2-CS-. NH2- 30 
S02-. X-NH-CO-. X2N-CO-. X-NH-
CS-. X2N-CS-. X-NH-S02-. X2N-S02-. 
X-CO-. X-CS-. X-S02-. X-0-CO-. or 
X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl. 
35 
C1_10 fluoroalkyl. C1_10 alkyl substituted with J. C1_10 
fluoroalkyl substituted with J. 1-adrnantyl. 9-fluorenyl. 
phenyl. phenyl substituted with K. phenyl disubstituted 
with K. phenyl trisubstituted with K. naphthyl. naph-
40 thyl substituted with K. naphthyl disubstituted with K. 
naphthyl trisubstituted with K. C1_10 alkyl with an 
attached phenyl group. C1_10 alkyl with two attached 
phenyl groups. C1_10 alkyl with an attached phenyl 
group substituted with K. cl-10 alkyl with two attached 45 
phenyl groups substituted with K. C1_10 alkyl with an 
attached phenoxy group. and cl-10 alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen. COOH. 50 
OH. CN. N02• NH2• C1_10 alkoxy. C1_10 alkylamine. 
C2_12 dialkylamine. C1_10 alkyl-0-CO-. C1_10 alkyl-
0-CO-NH-. and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen. C1_10 
alkyl, C1_10 perfloroalkyl. C1_10 alkoxy. N02. CN. OH. 55 
C02H. amino. C1_10 alkylamino. C2_12 dialkylamino. 
C1_10 acyl, C1_10 alkoxy-CO-. and C1_10 alkyl-S-; 
AA2 is a side chain blocked or unblocked amino acid with 
the L configuration. D configuration. or no chirality at 
the a-carbon selected from the group consisting of 60 
alanine. valine. leucine. isoleucine, proline. 
methionine. methionine sulfoxide. phenylalanine. 
tryptophan, glycine. serine. threonine. cysteine. 
tyrosine. asparagine. glutamine. aspartic acid. glutamic 
acid, lysine. arginine. histidine. phenylglycine. beta- 65 
alanine. norleucine. norvaline. alpha-aminobutyric 
acid. epsilon-aminocaproic acid, citrulline. 
28 
hydroxyproline. ornithine, homoarginine, sarcosine, 
indoline 2-carboxylic acid. 2-azetidinecarboxylic acid. 
pipecolinic acid (2-piperidine carboxylic acid). 
0-methylserine. 0-ethylserine. S-methylcysteine. 
S-ethylcysteine. S-benzylcysteine, NH2-CH 
(CH2CHEt2)-COOH. alpha-arninoheptanoic acid. 
NH2-CH(CH2-l-napthyl)-COOH. NH2-CH(CH2-2-
napthyl)-COOH. NH2-CH(CH2-cyclohexyl)-COOH. 
NH2-CH(CH2-cyclopentyl)-COOH. NH2-CH(CH2-
cyclobutyl)-COOH. NH2-CH(CH2-cyclopropyl)-
COOH. trifluoroleucine. and hexafluoroleucine; 
R2 is selected from the group consisting of C1__g branched 
and unbranched alkyl. C1_8 branched and unbranched 
cyclized alkyl. and cl-8 branched and unbranched 
fluoroalkyl; 
R4 is selected from the group consisting of C3_20 cyclized 
alkyl with an attached phenyl group. cl-20 alkyl with an 
attached phenyl group substituted with K. cl-20 alkyl 
with an attached phenyl group disubstituted with K, 
C 1_20 alkyl with an attached phenyl group trisubstituted 
with K, C3_20 cyclized alkyl with an attached phenyl 
group substituted with K. C1_10 alkyl with a moi:pholine 
ring attached through nitrogen to the alkyl. cl-10 alkyl 
with a piperidine ring attached through nitrogen to the 
alkyl. cl-10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl. C1_20 alkyl with an OH 
group attached to the alkyl, -CH2CH20CH2CH20H. 
cl-10 alkyl with an attached 4-pyridyl group, cl-10 
alkyl with an attached 3-pyridyl group. cl-10 alkyl with 
an attached 2-pyridyl group. -NH-CH2CH2-(4-
hydroxyphenyl). and -NH-CH2CH2-(3-indolyl). 
2. A peptide ketoamide compound of the formula: 
M 1-AA2-AARES-CO-NH-R 
or a pharmaceutically acceptable salt. wherein 
AARES represents -NH-CHR2-CO-, 
M1 represents H. NH2-CO-. NH2-CS-. NH2-
S02-. X-NH-CO-, X2N-CO-, X-NH-
CS-. X2N-CS-, X-NH-S02-. X2N-S02-. 
X-CO-, X-CS-, X-S02-. X--0-CO-, or 
X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl, 
C1_10 fluoroalkyl. C1_10 alkyl substituted with J. C1_10 
fluoroalkyl substituted with J, 1-admantyl. 9-fluorenyl, 
phenyl, phenyl substituted with K. phenyl disubstituted 
with K. phenyl trisubstituted with K, naphthyl, naph-
thyl substituted with K. naphthyl disubstituted with K, 
naphthyl trisubstituted with K. C1_10 alkyl with an 
attached phenyl group, C1_10 alkyl with two attached 
phenyl groups. C1_10 alkyl with an attached phenyl 
group substituted with K. cl-10 alkyl with two attached 
phenyl groups substituted with K. cl-10 alkyl with an 
attached phenoxy group. and cl-10 alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen. COOH. 
OH, CN, N02. NH2• C1_10 alkoxy. C2_12 to alkylamine. 
C2-12 dialkylamine. C1-10 alkyl-0-CO-, C1-10 alkyl-
0-CO-NH-. and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
perfluoroalkyl. C1_10 alkoxy, N02• CN, OH. C02H. 
amino, C1_10 to alkylarnino, C2 _12 dialkylarnino. 
C1-C10 acyl. C1_10 alkoxy-CO-. and C1_10 alkyl-S-; 
AA2 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration. or no chirality at 
5,650.508 
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the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, 
methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine. serine. threonine. cysteine. 
tyrosine, asparagine. glutamine, aspartic acid. glutamic 5 
acid. lysine. arginine. histidine. phenylglycine. beta-
alanine. norleucine, norvaline. alpha-aminobutyric 
acid, epsilon-aminocaproic acid. citrulline. 
hydroxyproline, ornithine. homoarginine, sarcosine. 
indoline 2-carboxylic acid. 2-azetidinecarboxylic acid. 10 
pipecolinic acid (2-piperidine carboxylic acid). 
0-methylserine. 0-ethylserine. S-methylcysteine. 
S-ethylcysteine. S-benzylcysteine. NH2-CH 
(CH2CHEt2)-COOH. alpha-arninoheptanoic acid, 
NH2---CH(CH2-l-napthyl)-COOH. NH2---CH(CH2-2- 15 
napthyl)-COOH. NH2-CH(CH2-cyclohexyl)-COOH. 
NH2---CH(CH2-cyclopentyl)-COOH. NH2---CH(CH2-
cyclobutyl)-COOH. NH2-CH(CH2-cyclopropyl)-
COOH. trifluoroleucine. and hexafluoroleucine; 
R2 is selected from the group consisting of C1-s branched 20 
and unbranched alkyl. cl-8 branched and unbranched 
cyclized alkyl. and cl-8 branched and unbranched 
fluoroalkyl; 
R4 is selected from the group consisting of C3_20 cyclized 
alkyl with an attached phenyl group. C1_20 alkyl with an 25 
attached phenyl group substituted with K. ~-2o alkyl 
with an attached phenyl group disubstituted with K. 
C 1_20 alkyl with an attached phenyl group trisubstituted 
with K. c3-20 cyclized alkyl with an attached phenyl 
group substituted with K. C1_10 alkyl with a morpholine 30 
ring attached through nitrogen to the alkyl. C1_10 alkyl 
with a piperidine ring attached through nitrogen to the 
alkyl. C1_10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl. C1_20 alkyl with an OH 
group attached to the alkyl. ---CH2CH20CH2CH20H. 35 
cl-10 alkyl with an attached 4-pyridyl group, cl-10 
alkyl with an attached 3-pyridyl group. cl-10 alkyl with 
an attached 2-pyridyl group. -NH-CH2CH2-( 4-
hydroxyphenyl). and -NH-CH2CH2-(3-indolyl). 
3. A peptide ketoamide compound of the formula: 
M 1-AA2-AARES-CO-NH-R4 
or a pharmaceutically acceptable salt, wherein 
AARES represents -NH---CHR2---CO-. 
40 
45 
M1 represents H. NH2-CO-. NH2-CS-. NH2-
S02-. X-NH-CO-. X2N-CO-. X-NH-
CS-. X2N---CS-. X-NH--S02-. X2N--S02-. 
X---CO-. X---CS-. X--S02-. X-0-CO-. or 
50 
X-0-CS-; 
X is selected from the group consisting of C1_10 alkyl. 
cl-10 fluoroalkyl. cl-10 alkyl substituted with J. cl-10 
fluoroalkyl substituted with J. 1-admantyl, 9-fluorenyl. 55 phenyl. phenyl substituted with K. phenyl disubstituted 
with K. phenyl trisubstituted with K. naphthyL naph-
30 
thyl substituted with K. naphthyl disubstituted with K. 
naphthyl trisubstituted with K. cl-10 alkyl with an 
attached phenyl group. cl-10 alkyl with two attached 
phenyl groups. cl-10 alkyl with an attached phenyl 
group substituted with K. cl-10 alkyl with two attached 
phenyl groups substituted with K. C1_10 alkyl with an 
attached phenoxy group. and C1_10 alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen. COOH. 
OH. CN. N02• NH2. C1_10 alkoxy. C1_10 alkylarnine. 
C2_12 dialkylamine. C1_10 alkyl-0-CO-. C1_10 alkyl-
0-CO-NH-. and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen. C1_10 
alkyl. C1_10 perfluoroalkyl. C1_10 alkoxy. N02. CN. 
OH. C02H. amino. C1_10 alkylarnino. C2 _12 
dialkylamino. C1-C10 acyL C1_10 -alkoxy-CO-. and 
C1_10 alkyl-S-; 
AA2 is a side chain blocked or unblocked amino acid with 
the L configuration. D configuration. or no chirality at 
the a-carbon selected from the group consisting of 
alanine. valine, leucine, isoleucine. proline. 
methionine. methionine sulfoxide. phenylalanine. 
tryptophan. glycine. serine, threonine. cysteine. 
tyrosine. asparagine. glutamine. aspartic acid. glutamic 
acid. lysine. arginine. histidine, phenylglycine. beta-
alanine. norleucine. norvaline. alpha-aminobutyric 
acid. epsilon-aminocaproic acid. citrulline. 
hydroxyproline. ornithine. homoarginine. sarcosine. 
indoline 2-carboxylic acid. 2-azetidinecarboxylic acid. 
pipecolinic acid (2-piperidine carboxylic acid). 
0-methylserine. 0-ethylserine. S-methylcysteine. 
S-ethylcysteine. S-benzylcysteine. NH2-CH 
(CH2CHEt2)-COOH. alpha-arninoheptanoic acid. 
NH2---CH( CH2-l-napthyl)-COOH. NH2---CH(CH2-2-
napthyl)-COOH. NH2---CH(CH2-cyclohexyl)-COOH. 
NH2---CH(CH2-cyclopentyl)-COOH. NH2---CH(CHr 
cyclobutyl)-COOH. NH2-CH(CH2-cyclopropyl)-
COOH. trifluoroleucine and hexafluoroleucine; 
R2 is selected from the group consisting of C1-s branched 
and unbranched alkyl. C1_8 branched and unbranched 
cyclized alkyl, and C 1-s branched and unbranched 
fluoroalkyl; 
R4 is selected from the group consisting of C1_10 alkyl 
with a morpholine ring attached through nitrogen to the 
alkyl. cl-10 alkyl with a piperidine ring attached 
through nitrogen to the alkyl. cl-10 alkyl with a pyr-
rolidine ring attached through nitrogen to the alkyl. 
C1_20 alkyl with an OH group attached to the alkyl. 
-CH2CH20CH2CH20H. C1_10 alkyl with an attached 
4-pyridyl group. cl-10 alkyl with an attached 3-pyridyl 
group. cl-10 alkyl with an attached 2-pyridyl group. 
-NH-CH2CH2-(4-hydroxyphenyl). and -NH-
CH2CH2-(3-indolyl). 
* * * * * 
